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Background. VAV interacting Krüppel-like factor (VIK) is a novel transcription factor. 
Previously our lab reported a series of breast cancer tumour samples where VIK 
methylation was associated with an increased risk of recurrence in tamoxifen-treated 
patients, indicating a role for VIK in ER positive breast cancer and endocrine resistance. 
Additionally VIK has been shown to be involved in cell cycle regulation, interacting with 
CDK4 and VAV1. The cyclin D-CDK4/6-Rb pathway is frequently dysregulated in ER positive 
breast cancer. Combined treatment of palbociclib, a highly selective CDK4/6 inhibitor, with 
endocrine therapy substantially improved outcome of patients with ER positive metastatic 
breast cancer. Increasing clinical use means acquired resistance to palbociclib is emerging 
as a major clinical challenge.  
 
Results. VIK was confirmed to be subject to regulation by DNA methylation in breast 
cancer. VIK methylation correlated to transcriptional silencing of mRNA in both cancer cell 
lines and primary tumours. To determine the functional significance of loss of VIK 
expression, VIK was knocked down in unmethylated breast cancer cell lines and a normal 
breast epithelial cell line. Knockdown resulted in cell death via induction of apoptosis. VIK 
knockdown altered cell cycle progression from G1 to S phase. Expression of multiple 
regulatory cell cycle proteins was altered, differentially in normal and tumour cells. 
Treatment with the CDK4/6 inhibitor, palbociclib, in cells with reduced VIK expression 
resulted in decreased sensitivity to the drug, inducing a shift in IC50 value towards 
resistance. In a model of acquired resistance, T47D cells were cultured long-term with 
palbociclib generating resistant clones. VIK was significantly downregulated in all resistant 
clones to barely detectable mRNA levels, suggesting a role for VIK in resistance to CDK4/6 
inhibition. 
 
Conclusion. This PhD has confirmed VIK is a novel epigenetically regulated gene in breast 
cancer. VIK expression is essential to both normal and tumour breast cell survival and is 
involved in the regulation of the G1/S phase transition in the cell cycle. Loss of VIK 
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1.1 Breast Cancer 
Breast cancer is a leading cause of death by cancer in women of the Western world. Breast 
cancer has a yearly incidence of over 1.3 million, this accounts for 23% of all malignancies 
(3). In the UK alone, every year nearly 55,000 people are diagnosed with breast cancer. 
Women have a 1 in 8 chance of being diagnosed with breast cancer in their lifetime, and 
nearly 12,000 people die of breast cancer each year (4). 
As with the majority of cancers, breast cancer is a complex disease and presents a 
multifactorial aetiology. There are a wide range of risk factors from age, lifestyle, and diet 
to family history and genetic and epigenetic alterations in the genome. The nature of the 
cancer significantly influences prognosis and risk of recurrence (5).  
1.1.1 Breast Cancer development  
The normal breast is made up of a system of branched epithelial tubes, called ducts, which 
connect the lobules to the nipple where milk is secreted (Figure 1.1A). The lobules contain 
secretory units called acini. The lobules and the distal end of the duct form the terminal 
duct lobular unit (TDLU). The ducts of the breast are lined by a single layer of epithelial 
cells, surrounded by a layer of myoepithelial cells or basal cells, which are encircled by a 
basement membrane made up of laminin and collagen. This whole structure is surrounded 
by connective tissue and embedded into adipose tissue (6). 




Figure 1.1. Anatomy of the human breast and breast cancer development. A) Each mammary 
gland contains 15-20 lobes, which contain a series of branched ducts that drain into the nipple. B) 
The normal duct consists of a layer of epithelial cells surrounded by myoepithelial cells. Ductal 
carcinoma starts as a benign epithelial lesion defined by an abnormal structure of the duct, which 
develops into atypical hyperplasia with an additional layer within the lumen. The hyperplasia 
proliferates into in situ carcinoma, which develops into invasive carcinoma.  
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Breast carcinoma arises from the mammary epithelium and most commonly the epithelial 
cells of the TDLU (Figure 1.1B). Breast cancer development is thought to begin with a 
benign epithelial lesion characterised by abnormal structure of the breast duct or lobule. 
This evolves into atypical hyperplasia where an extra cell layer grows within the lumen. 
These cells grow and proliferate into an early stage in situ carcinoma. This develops into 
invasive breast cancer, with cells reaching towards the nearest blood vessels and then 
lymph vessels to cause metastatic spread (7, 8).  
1.1.2 Breast Cancer Classification  
Breast cancer diagnosis is based on clinical examination of the breast and lymph nodes, 
followed by a mammogram and a core biopsy or fine-needle aspiration. Breast cancer is 
widely considered as a highly heterogeneous disease. Different types of breast carcinoma 
vary in histopathological and biological features, different clinical outcome and response to 
therapies. Therefore, clinically, breast cancer cannot be treated as one single disease and is 
instead classified into more homogenous subgroups. A variety of clinical and pathological 
factors are routinely used to categorise breast cancer to assess prognosis and guide 
treatment strategy. These include patient age, tumour size, histological features and 
lymphovascular migration (9). 
Breast cancer can be broadly divided into in situ carcinoma and invasive carcinoma. In situ 
carcinoma is a benign disease, characterised by localised uncontrolled proliferation of cells 
into the lumen of the ducts or lobules, but with no invasion into the surrounding breast 
tissue. In situ carcinoma is further sub-classified as either Ductal Carcinoma in situ (DCIS) or 
lobular carcinoma in situ, based on the cells of origin within the TDLU (10). Ductal 
carcinoma is considerably more common than lobular carcinoma, accounting for 80% and 
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15% of in situ carcinomas respectively (11). DCIS are classified into histological grades 
based on degree of cell differentiation. Grade 1 (low) is characterised by small, 
undifferentiated cells with small nuclei and absence of necrosis. Grade 3 (high) comprised 
highly atypical and differentiated cells with multiple nuclei and a high proliferative rate and 
presence of necrosis. Grade 2 represents an intermediate group (12). Ductal carcinoma in 
itself is not life threatening, but is often seen as a precursor to invasive carcinoma (13, 14).  
Invasive breast carcinoma describes a group of heterogeneous malignant cancers, which 
have invaded into the surrounding breast tissue and have the potential to metastasise. 
Histological classification is not sufficient to fully describe the heterogeneity of invasive 
breast cancers, however advances in molecular understanding along with gene expression 
profiling has helped refine breast cancer classification. Such classification is especially 
relevant when considering the treatment for invasive and metastatic breast cancers. 
Molecular biomarkers have been utilised to determine breast cancer subtypes. The 
predominant markers are the hormone receptors, estrogen receptor (ER) and 
progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2/neu) 
(15). During histological examination, samples are routinely evaluated for presence of 
these markers by immunohistochemistry and/or fluorescence in situ hybridisation (FISH). 
Based on the presence or absence of these markers, breast cancer can be divided into 
three main groups: Triple Negative, negative for all three markers, hormone receptor 
positive, expressing ER and/or PR and HER-2 enriched, where HER2 is amplified (16). 
Further to this, gene expression profiling and many studies evaluating patterns of gene 
expression support 4 main intrinsic breast cancer subtypes that have prognostic relevance; 
luminal A, luminal B, HER2+ and basal-like (17-19).  
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The luminal subtypes share expression of the estrogen receptor and/or progesterone 
receptor and have better overall survival than the HER2 and basal-like subtypes. Luminal A 
breast cancers, account for approximately 40% of breast cancers, are characterised by high 
estrogen receptor signalling and under-expression of HER2. These cancers tend to be 
associated with a more favourable prognosis (20). Luminal B, corresponding to 
approximately 20% of cases, tends to have lower ER regulation, a higher proliferation rate 
and correlates with a worse prognosis and higher tendency to relapse (21, 22). HER2+ 
represents 20-30% of all diagnosed breast cancers, and exhibit over expression of HER2, 
with under-expression of luminal-associated genes (23). Basal-like tumours account for up 
to 15% of all breast cancers. These tumours primarily exhibit no expression of ER, PR or 
HER2, but are a highly heterogeneous sub-group of breast cancers (24, 25) and have been 
sub divided in up to 6 separate subtypes (26). The highly diverse nature of breast cancer, 
and increasing understanding of molecular markers and genetic profiling, means subtyping 
and classification is subject to changes and adjustments all of the time.  
1.1.3 Estrogen receptor positive breast cancer 
Estrogen is essential to normal female physiology, reproduction and behaviour. Sustained 
exposure to endogenous or exogenous estrogen is a well-established cause of breast 
cancer (27, 28).  
ER expressing breast cancers represent the majority of breast cancers, approximately 60-
70% of all breast cancers (29). Estrogen plays a key role in the initiation and progression of 
these carcinomas. The action of estrogen is mediated by two estrogen receptors, ER-α and 
ER-β. The two receptors are encoded by separate genes located on different 
chromosomes. ESR1, encoding ER-α, and ESR2, encoding ER-β, are located on chromosome 
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6 and chromosome 14 respectively (30, 31). They have an overall similar structure, 
consisting of a central DNA-binding domain, flanked by two transcriptional activation 
domains. An N-terminal AF1 domain and a C-terminal ligand binding region containing an 
AF2 domain. This AF2 domain also mediates interactions with co-activators that increase 
ER transcriptional activity (32, 33). 
ER are members of the nuclear hormone receptor family and function as ligand-dependent 
transcription factors (34). ER signalling regulates a diverse range of cellular functions 
including proliferation, apoptosis, invasion and angiogenesis. ER-α is responsible for many 
of the actions of estrogen on both normal and cancerous tissue, through ligand activated 
transcriptional regulation (genomic actions) and by acting as a component of membrane 
and cytoplasmic signalling cascades (non-genomic actions) (35). The ER is activated by 
estrogen, which exists in three forms estrone (E1), estradiol (E2) and estriol (E3). E2 is the 
most potent ER activating ligand (36). ERα comprises an N-terminal AF1 domain, a DNA 
binding domain, and a C-terminal ligand binding region that contains an AF2 domain (37).  
The classical mechanism of ER action is via its genomic actions. This involves binding of 
estrogen, upon which the receptor dimerises and translocates to the nucleus, binds to 
endocrine response elements in the regulatory region of the target genes and stimulates 
gene transcription. Emerging evidence indicates ER signalling is complex, and includes 
multiple co-regulatory proteins, and involves a number of pathways beyond the classical 
genomic signalling (38) (Figure 1.2).  




Figure 1.2 Estrogen Receptor signalling pathways. Four different signalling pathways have been 
recognised in which ER leads to cell proliferation and survival (38). Pathway A is the classical 
genomic pathway. When estradiol binds, ER dimerises and relocates to the nucleus where it binds to 
EREs and recruits co-activators that will activate transcription of target genes. Pathway B is the non-
classical genomic pathway, involving interaction of ER with other transcription factors such as AP-1. 
Pathway C is estradiol independent, whereby growth factors activate ER via phosphorylation. 
Pathway D is a non-genomic pathway involving estrogen receptors that are located close to the cell 
membrane. ER activates Akt, MAPK signalling via recruitment of kinases such as Src and PI3K. (ER: 
Estrogen Receptor. ERE: Estrogen Response Element. RE: Response Element. TF: Transcription 
Factor. p: phosphorylation site. RTK: Receptor Tyrosine Kinase. E2: Estradiol. CoA: Co-activator) 
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1.1.3.1 Hormone therapies for treatment of ER positive breast cancer 
 
In the first instance breast cancer is normally treated by surgery to remove the tumour. 
Adjuvant therapies such as radiation or endocrine therapy may be considered before 
surgery to reduce the tumour mass for operation and/or after surgery to reduce risk of 
recurrence and metastasis.  
Interfering with the action of estrogen is been the mainstay of treatment for ER+ breast 
cancer and the treatment methods most commonly used in the clinic for ER positive 
cancers are hormone therapies. Current endocrine strategies either target the ER itself, 
with selective estrogen receptor modulators (SERMS), or suppress the amount of available 
estrogen. This would be via gonadal suppression in premenopausal women e.g. luteinising 
hormone releasing agonists, or with aromatase inhibitors in postmenopausal women.  
SERMS such as tamoxifen and fulvestrant, bind to ER, inhibiting estrogen from binding and 
initiating oncogene expression and cellular proliferation. Tamoxifen is the most established 
SERM, and has significant effect on breast cancer proliferation. Adjuvant therapy with 
tamoxifen almost halves the rate of disease recurrence and reduces the annual breast 
cancer death rate by a third (39). Fulvestrant, however, in addition to blocking the estrogen 
receptor, also downregulates the receptor (40). Aromatase inhibitors, such as anastrozole 
and letrozole, block estrogen synthesis via inhibition of aromatase, the enzyme that 
converts androgens to estrogens (41). 
Due to their proven efficacy and generally favourable side effects, these endocrine 
therapies are widely used for both early-stage, recurrent and metastatic breast cancer. 
However, despite their effectiveness, 50% of patients will relapse. Not all patients respond 
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to first line endocrine therapy, due to de novo resistance, whereas others develop acquired 
resistance and eventually relapse despite the initial response (42). One third of all women 
treated with tamoxifen for 5 years will develop recurrent disease within 15 years (39). 
1.1.3.2 Resistance to hormone therapies 
 
Of all breast cancer patients 30-40% fail to respond to initial therapy and exhibit intrinsic 
resistance to such therapies (43). The primary mechanism of such de novo or intrinsic 
resistance to endocrine therapy is lack of ER-α expression. Additionally, approximately 8% 
of all Caucasian women have inactive alleles of cytochrome P450 2D6. These patients are 
less sensitive to tamoxifen, as they are unable to covert the drug to its active metabolite, 
endoxifen (44, 45).  
The majority of patients acquire resistance to endocrine therapy over the course of 
treatment. Many processes have been proposed to mediate this acquired resistance 
following prolonged treatment with endocrine therapies. Deregulation of various aspects 
of estrogen signalling is a common mechanism.  Additionally tumour cells can develop 
mechanisms that provide an alternative, ER independent pathways for proliferation and 
survival. Such adaptive mechanisms can result from genetic or epigenetic changes within 
the tumour that drive hormone-independent mitogenic pathways (46, 47). 
ER can regulate gene expression though protein-protein interactions with other 
transcription factors such as activator protein 1 (AP1), specificity protein 1 (SP1) and 
nuclear factor-κB (NF-κB). Increased transcriptional activity of these is associated with 
endocrine resistance (48, 49). 
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Anti-estrogen treatments act as cytotoxic agents but also have cytostatic properties, 
decreasing proliferation and leading to specific G1 phase cell cycle arrest (50). Therefore 
atypical expression of estrogen dependent and independent cell cycle regulators can 
confer endocrine resistance. For example c-myc is implicated in endocrine resistance (51) 
through driving estrogen independent cell proliferation, mimicking the estrogen stimulated 
activation of CDK2/cyclin E (51, 52). Amplification of both cyclin D (53-55) and cyclin E (56, 
57) has been connected to tamoxifen resistance. Over-expression of cyclin D1b specifically 
has been shown to overcome the effect of anti-estrogen therapy (58). Tamoxifen is known 
to alter both p27 and p21 expression, and loss of these inhibitors is implicated in anti-
estrogen resistance (59). There is transcriptional repression of p21 (60), this loss of p21 
releases the inhibitory effect on cyclin E-CDK2, driving cell cycle progression independent 
of ER. There is also data that suggests in endocrine resistant cancers, pathways such as 
HER2 and AKT/PI3K can enhance CDK4/6-cyclin D signalling independent of ER (61, 62). 
Upregulation of growth factors is widely considered a key resistance mechanism. Increased 
expression of EGFR, HER2 and IGF1 can confer tamoxifen resistance, along with members 
of their downstream signalling, particularly ERK and PI3K (63-65). In fact, overexpression of 
HER2 is one of the best characterised mechanisms of endocrine resistance. Loss of 
transcriptional repressors i.e. FOXP3 (66), GATA4 (67) and PAX2 (68) as well as gene 
amplification might be responsible for increased HER2 receptor expression.  
The PI3K-Akt-mTOR pathway, a complex pathway activated in response to tyrosine kinase 
receptors and growth factors, is an essential cell survival pathway. Activation of this 
pathway, through either overexpression of fibroblast growth factor receptor or HER2, is 
considered to be involved in endocrine resistance (69, 70). Increased signalling through this 
Chapter 1: Introduction 
28 
 
pathway can drive cell proliferation and anti-apoptotic responses. Additionally inhibition of 
mTOR has been shown to restore response to tamoxifen (64). A hallmark of resistance to 
drug treatment is the upregulation of pro-survival mechanisms and inhibition of apoptotic 
pathways. There is accumulating evidence for increased expression of anti-apoptotic 
molecules in endocrine resistance, for example BCL-2 and BCL-XL, coordinated with 
decreased expression of pro-apoptotic molecules BAK, BIK and caspase 9 (71). Although, 
this is potentially a consequence of activation of proliferation signalling through the PI3K-
Akt pathway. Inhibition of the PI3K/mTOR pathway has received much attention in recent 
years for use either alone or in combination with hormone therapies in both primary 
disease and advanced cancers. Multiple compounds have been developed to inhibit 
various aspects and are in preclinical development or clinical trials already (72, 73). 
Increased understanding of resistance mechanisms provides avenues for new treatment 
strategies to overcome resistance. Identification of novel therapies for use as a single agent 
or in combination with endocrine therapies is essential for patients who have relapsed 
following endocrine treatment.  
1.2 Epigenetics  
Epigenetics describes heritable changes in gene expression that are not due to alteration in 
the DNA sequence. The main features of epigenetic regulation involve chemical 
modifications to DNA or to the proteins associated with DNA, such as histones, which form 
the cores of chromatin packaging i.e. DNA methylation or histone modifications (Figure 
1.3). A prominent role for non-coding RNAs is also emerging (74). Either by DNA 
methylation or histone modifications, epigenetic changes play a crucial role in the 
regulation of gene expression.  
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Diverse biological properties can be affected by epigenetic mechanisms. Epigenetic 
changes are crucial for the development and differentiation of the various cell types in an 
organism (75), as well as for normal cellular processes such as X-chromosome inactivation 
in female mammals. However, epigenetic states can become disrupted by environmental 
changes. Epigenetic defects can develop over time and are inherited by the daughter cells 
(76). Therefore the importance of epigenetic changes in the development of cancer and 
the potential for use as therapy and prognostic biomarkers is increasingly being 
appreciated. 
1.2.1 Non-coding RNAs 
 
Non-coding RNAs (ncRNAs) refer to RNAs that are transcribed from DNA but do not encode 
a protein. However, lack of an encoded protein does not directly mean these RNAs do not 
hold information or have a biological function. These ncRNAS can be separated into short 
ncRNAs (<30 nucleotides) and long ncRNAs (>200 nucleotides) (77). 
Long ncRNAs are a diverse group of transcribed RNA molecules, thought to encompass 
nearly 30,000 human transcripts (78). Long ncRNAs have been described to have a range of 
functions including regulation of alternate splicing (79), directing imprinting (80, 81) and 
may serve as precursors to short ncRNAs (82). Increasing evidence suggests a role in 
epigenetic modulation, via an ability to complex with chromatin modifying proteins and 
recruiting their catalytic activity to specific regions within the genome. Long ncRNAs have 
been shown to bind to both chromatin repressing (83-85) and enhancing (86-88) 
complexes, thereby modulating chromatin states and altering gene expression (89).  
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Short ncRNAs are best known to function in regulating mRNA transcripts and include PIWI 
interacting RNAs (piRNAs), microRNAs (miRNAs), and small interfering siRNAs (siRNAs). 
piRNAs are single stranded RNAs produced in clusters and cleaved to individual units. They 
then bind to PIWI proteins, a subset of the Argonaute proteins, inducing epigenetic 
regulation and transposon control (90). miRNA are single stranded RNAs produced via 
transcription or through splicing, which fold into hairpin loop structures. These are then 
processed by the RNAse III endoribonuclease, Dicer, before being denatured. One of the 
RNA strands assembles with Argonaute proteins into the RNA induced silencing complex 
(RISC), which then targets specific mRNA containing the complementary sequence to the 
miRNA, to induce either cleavage or degradation, inhibiting translation of the protein (91). 
siRNAs are produced as double stranded RNAs, that can enter the post-transcriptional gene 
silencing pathway which via RISC, leads to mRNA degradation, or can enter the 
transcription gene silencing pathway involved in chromatin modification (92).  
The majority of ncRNAs do not yet have a described function and potentially these RNAs 
still have roles in epigenetic mechanisms that are not yet completely understood (93). 
1.2.2 Histone modifications 
Histones are the small proteins that pack and order the DNA into nucleosomes. Each 
nucleosome contains two subunits of each histone H2A, H2B, H3 and H4. Together they 
form a structure around which the DNA is coiled, forming the nucleosome. H1 and H5 
function as linkers. A flexible N-terminal tail on each histone protrudes from the core (94). 
Multiple different types of modification of the histone tail have been described such as 
histone acetylation, methylation, phosphorylation and ubiquitination. Such modifications 
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of the histone tail can dynamically modify the chromatin structure, altering activation or 
repression of gene transcription (95).  
Histone acetylation is the most widely studied and most common modification. Histone 
acetyltransferases (HAT) and histone deacetylases (HDACs) regulate acetylation of histone 
tails. Lysine residues within H3 and H4 are preferential targets for histone acetylation. 
Acetylation is largely targeted to promoter regions. Presence of an acetyl group on the 
histone tail is associated with an open chromatin structure and therefore correlates with 
active gene transcription. Whereas deacetylation causes the chromatin to adopt a closed 
structure, silencing transcription (96, 97). Therefore histone modifications are one of the 
key mechanisms in regulating gene expression and consequently have been found to be 
disturbed in multiple disease types, including cancer.  
Histone modification and DNA methylation may be closely related. Methylation of DNA 
may lead to modification of histones, which would cause the chromatin to assume a closed 
condensed form, thereby preventing transcription of the gene at that site (98). 
1.2.3 DNA methylation 
 
DNA methylation is a modification of the 5th position of the pyrimidine ring in a cytosine 
that precedes a guanine nucleotide. DNA methylation occurs by addition of a methyl group 
at the 5’ carbon of the cytosine ring, resulting in 5-methylcytosine. The addition of a 
methyl group is carried out by DNA methyl transferases (DNMTs), a family of enzymes 
including DNMT1, DNMT3a and DNMT3b. DNMT1 appears to be responsible to maintaining 
inherited patterns of methylation, whilst DNMT3a and DNMT3b mediate establishment of 
new, de novo, methylation patterns (99). In mammalian DNA, 5-methylcytosine is found in 
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approximately 5% of genomic DNA, primarily at cytosines that precede guanines in the 
nucleotide sequence (100). A cytosine next to a guanine in the DNA sequence is called a 
CpG dinucleotide or CpG site. Such CpG dinucleotides tend to be grouped together in small 
regions of DNA rich in CpG sites, known as CpG islands. These CpG islands have a G+C 
content of greater than 50% and account for 1-2% of the genome (101-103). Typically CpG 
islands are found spanning the 5’ regulatory region of genes, where transcription is 
initiated (104). In fact, CpG islands overlap the promoter regions of 60-75% of all human 
genes (105). DNA hyper-methylation of these CpG islands is associated with transcriptional 
silencing of genes and thereby loss of gene function, as well as genomic instability through 
silencing of DNA repair genes. DNA methylation silences gene expression via two main 
mechanisms; the methyl group projects into the major groove of the DNA and actively 
inhibits transcription, by either blocking transcription factor binding through steric 
hindrance or recruiting additional proteins to block transcriptional activation (106). 
1.2.3.1 DNA methylation in breast cancer 
 
Methylation plays an important role in normal cells as well as cancer development. DNA 
methylation contributes to chromatin organisation and tissue-specific gene expression. In 
normal cells, DNA methylation is essential in genomic imprinting i.e. the mechanism by 
which mammals express genes inherited through the paternal or maternal chromosome 
only. The selective gene expression is achieved through differential methylation of DNA 
regions of specific genes on the appropriate chromosome (107). 
In normal cells CpG dinucleotides tend to be unmethylated within the promoter region and 
methylated across the rest of the genome. The reverse is generally seen in cancer cells 
(108). Such alterations in the methylation of promoter regions in cancer cells are an 
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important mechanism in carcinogenesis, where methylation can switch off genes that 
would otherwise suppress tumorigenesis. When CpG islands that are normally hypo-
methylated become hyper-methylated important genes such as tumour suppressor genes, 
DNA repair genes or inhibitors of angiogenesis or cell adhesion may be transcriptionally 
repressed. In fact epigenetic gene inactivation is thought to be at least as common, if not 
more frequent than genetic mutation in cancer development (109-112).  
Many studies have established hyper-methylated genes in breast cancer and whole 
genome approaches have attempted to identify methylation signatures of breast cancer 
cells (113-116). In fact de novo methyl transferase DNMT3b is overexpressed in breast 
tumours (117) suggesting involvement of methylation alterations in tumourigenesis. DNA 
methylation of the hormone receptors, ER and PR has been proposed as a mechanism for 
hormone receptor negative tumours and implicated in resistance to hormone therapies 
(118-121). Among other methylated genes are those involved in cell cycle and 
proliferation, such as the cell cycle inhibitors p16 (122, 123) and 14-3-3-σ (124), 
methylation dependent silencing of these genes would override regulation of growth 
signals. DNA methylation has been implicated in promoting epithelial-mesenchymal 
transition (EMT) and metastasis through the inhibition of metastasis suppressing genes 
such as CREB3L1 (125), SDPR (126) and TES (127). DNA methylation in the promoter region 
has been detected in genes involved in DNA damage repair such as BRCA1 (128-130), 
MGMT (131) and mismatch repair genes hMLH1 and hMSH2 (132). Silencing of these genes 
could increase frequency of sporadic mutations, a hallmark of cancer. Hyper-methylation 
of such DNA damage response genes has been associated with simultaneous hypo-
methylation of anti-apoptotic/pro-survival genes such as DR4, FLIP and RNF8 (133) 
promoting cell growth and survival. 
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DNA methylation has been implicated in multiple processes promoting breast cancer 
development, tumour cell proliferation and metastasis. Understanding the epigenetic 
changes in breast cancer is important to comprehend the mechanics of breast 










Figure 1.3 Schematic representation of epigenetic regulation. DNA is organised by 
wrapping around histones to form nucleosomes. Histone modifications such as acetylation, 
are post-translational modifications that occur to the histone tail, altering the chromatin 
structure and accessibility of the DNA to the transcription machinery. DNA methylation is 
the covalent attachment of a methyl group by DNA methyltransferases (DMT) to a cytosine 
that precedes a guanine, thereby leading to transcriptional silencing (M: methyl group Ac: 
Acetyl group). 
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1.3 The Cell Cycle 
1.3.1 Regulation of the cell cycle 
The cell cycle comprises a series of tightly controlled events that drive the replication of 
DNA and cell division. It is divided into several phases; G1 in which cells prepare the 
machinery for replication, S phase involving duplication of the DNA, G2 a secondary gap 
phase and M phase in which the mitosis and cytokinesis takes place, and therefore 
proliferation. Cells then start a new cycle or remain in G0 state, quiescence, a distinct state 
from which cells can re-enter the cell cycle. The restriction point (R) is defined as the point 
of no return in G1, after which the cell is committed to enter the cell cycle (134). In the 
normal cell, several checkpoints throughout the different phases are controlled by 
activation and inactivation of a complex system of modulators (Figure 1.4). This ensures 
orderly execution through each of the cell cycle events. Cancer cells have acquired features 
that allow them to override these checkpoints leading to uncontrolled proliferation (135). 
The transitions between the cell cycle phases are controlled by a small number of protein 
kinases. Cyclin dependent kinases (CDKs) are a family of serine/threonine kinases that are 
activated at specific points of the cell cycle and require binding of cyclins for full activity. 
Members of the CDK family are characterised by an ATP-binding pocket, a PSTAIRE helix, 
which acts as a cyclin binding domain, and an activating T-loop motif. Activation of the CDK 
involves binding of the appropriate cyclin causing a conformational change which displaces 
the T-loop and exposes the substrate binding interface (136, 137). In total, at least 9 CDKs 
and 16 cyclins have been described in the literature (138). Different members of the CDK 
family, in association with particular cyclins, control key events throughout the cell cycle. 
CDK1 controls progression from G2 to mitosis and CDK2/CDK4/CDK6 control G1 to S phase. 
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CDK4 and CDK6 are structurally related proteins with many biological and biochemical 
similarities, within the cell cycle they are functional homologues (137). In addition to these 
there are regulatory CDKs such as CDK7 and transcriptional CDKs, including CDK8 and CDK9 
(139).  
The cyclins are a more diverse family of proteins and are divided into four classes, type A, 
B, D, and E cyclins. Cyclins are characterised by the presence of a cyclin box, required for 
binding to CDKs (140). The cyclins act as regulatory subunits to the CDKs and provide 
specificity of function at precise times during the cell cycle. CDK proteins remain at stable 
levels throughout the cell cycle, whilst the cyclin levels undergo phase dependent 
fluctuations. The sequential accumulation of different cyclins allows the formation of 
specific cyclin–CDK complexes that control progression through the cell-cycle phases (141). 
On the other hand, targeted degradation of partner cyclins inactivates CDKs when they are 
no longer required. For example, cyclin B is actively degraded by proteolysis mediated by 
the ubiquitin ligase, anaphase promoting complex (APC) (142). Cyclin D is particularly 
unstable, with a half life of less than 30 minutes, and shuttles to the nucleus during G1 
phase and is exported to the cytoplasm during S-phase (143). Phosphorylation of threonine 
286 by glycogen synthase kinase-3beta (GSK-3beta) actively promotes export of the 
protein and rapid degradation via ubiquitination (144, 145).  
Two distinct families of CDK inhibitors have been identified, INK4 and Cip/Kip, which can 
counteract CDK activity. These proteins inhibit CDK catalytic activity by allosteric 
competition with their cyclin binding partners. The INK4 family includes p15, p16 and p18. 
These specifically bind to CDK4 and CDK6. The INK4 proteins weaken the binding of cyclin D 
with CDK4 and CDK6 and interact with the catalytic domain of the kinases to effectively 
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suppress kinase activity (146). In this way CDK4 and CDK6 can be inactivated when INK4 
proteins are induced by anti proliferative signals, such as TGFβ (p15) (147), senescence 
(p16) (148) and terminal differentiation (p18) (149, 150). INK4 proteins can interact with 
both cyclin bound CDKs and monomeric CDKs. In the case that the CDK-cyclin D complex is 
already formed, the INK4 can inhibit without dissociating the cyclin. When binding to 
individual CDK subunits, INK4 binding interferes with subsequent CDK-cyclin complex 
formation (148), via competing with Cdc37, a chaperone protein required for the assembly 
of the CDK4/6-cyclin D complex (151, 152).  
The Cip/Kip family including p21, p27 and p57 interact with a broader spectrum of CDKs 
and can bind to CDK2, CDK4 or CDK6 (153, 154).  In response to inhibitory signals such as 
TGF-β, DNA damage or senescence, these cell cycle inhibitors are rapidly upregulated to 
inhibit cell cycle progression (155, 156) via negative regulation of CDKs. However, in 
proliferating cells, Cip/Kip family members can positively regulate CDK4/6 by facilitating 
their complex formation with cyclin D in early G1 (157). For example, in response to 
inhibitory signals including TGFβ (156) and drug treatment (158), p27 will bind to and 
inactivate CDK2, inducing cell cycle arrest. However, in proliferating cells, phosphorylation 
at tyrosine residues 88 and 89, within the CDK interacting domain, alters p27 to a 
noninhibitor (157). In this state, p27 can bind to and is sequestered by active CDK4-cyclin D 
complexes, freeing CDK2 from inhibition via p27. In turn p27 is then phosphorylated at 
threonine 187 by active CDK2-cyclin E, targeting the protein for degradation (159, 160). 
Therefore p27 balances cell proliferation and arrest via association with CDK4 or CDK2 
respectively (161). 
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In addition to CDK inhibitors, and degradation of partner cyclins, CDKs can also be 
reversibly inactivated by phosphorylation of crucial tyrosine and threonine residues within 
the ATP binding loop (162, 163). Most CDKs have both inhibitory and activating 
phosphorylation sites. Phosphorylation within the ATP-binding site by inhibitory kinases 
interferes with ATP alignment, thereby inhibiting kinase activity (164). Conversely, 
phosphorylation within the T-loop by CDK activating kinases (CAK) will enhance substrate 
binding and stability of the complex, allowing for full CDK activation (165). Cdc25 is a family 
of 3 phosphatases (Cdc25 A,B,C) that contribute to cell cycle control via dephosphorylation 
of CDKs allowing for sequential activation. CDK2 phosphorylation at tyrosine 15 and 
threonine 14 residues blocks cells in G1, but dephosphorylation by Cdc25A enables entry 
into S-phase (166). CDK1 is phosphorylated by Wee1 (167), and unless CDK1 is 
dephosphorylated at tyrosine 15 by Cdc25C cells will arrest at the G1/M transition (168).  
All of these regulatory elements come together to ensure orderly progression through the 
cell cycle phases. G1 is an intermediate phase occupying the time between cell division in 
mitosis and the DNA replication in S-phase. During G1 cells grow in preparation for DNA 
replication and intracellular components, such as centrosomes, undergo replication. In G1 
the retinoblastoma protein (Rb) directly binds to the transactivation domain of E2F, and 
recruits chromatin modifying enzymes, actively repressing E2F mediated transcription 
(169). Upon mitogenic signalling, D-type cyclins (D1, D2, D3) are synthesised and form a 
complex with CDK4 and CDK6. CDK4/6-cyclin D complexes phosphorylate Rb, which 
becomes partly inactive, lifting its repression of E2F. Free E2F is active and induces 
transcription of S phase specific genes, including cyclin E gene transcription (170). This 
provides a positive feedback loop, whereby cyclin E forms a complex with CDK2, which 
further phosphorylates and inactivates Rb. This leads to complete dissociation of E2F1, 
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initiating further transcription of S phase genes (171). At this point, so called the restriction 
point, cells are committed irreversibly to undergo transition from G1 to S phase. This 
progression from G1 to S phase is a crucial checkpoint in protecting cells from abnormal 
replication. Cells may be halted at this checkpoint to repair any damage. For example, in 
response to DNA damage p53 stimulates transcription of several genes, including p21, 
which inhibits both CDK2 and CDK4/6, halting cells in G1 (172).   
CDK2 is further activated by cyclin A2 to progress through S-phase, where the cell 
duplicates its chromosomes. Autoregulatory negative feedback loops subsequently 
suppress transcription of G1-S phase genes once cells have advanced into S-phase (173). 
Phosphorylation of E2F transcription factors by CDK2-cyclin A results in their release from 
target promoters, inactivating transcription (174), and E2F proteins are targeted for 
degradation via ubiquitination (175, 176). As well as proteins necessary for completion of 
S-phase, CKD2-cyclin A complexes phosphorylate numerous proteins involved in 
transcription and DNA replication and repair (177). Once the DNA is replicated the cells 
enter a second gap phase. G2 is the interval between completion of DNA replication and 
onset of mitosis, and acts as a checkpoint to ensure DNA replication has been completed 
without mistake or damage. In response to DNA damage, cells can be halted at this 
checkpoint to complete DNA replication or repair damaged DNA (178). DNA damage is 
associated with many cellular events, including activation of Chk1 (Checkpoint kinase 1). 
Chk1 inactivates the phosphatase Cdc25C, maintaining CDK1 in an inactive state and thus 
causing G2-M arrest (163, 179).  
Finally CDK1 associates with cyclins A and B to control progression from G2 and onset of 
mitosis. Cyclin A is accumulated during G2 and mediates entry into mitosis. At the end of 
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interphase, CDK1 is activated by A-type cyclins, enabling progression from G2 and onset of 
mitosis. Once the nuclear envelope has broken down, type A cyclins are degraded by 
ubiquitin-mediated proteolysis. Cyclin B proteins are actively synthesised and associate 
with CDK1 to drive cells through mitosis. CDK1-cyclin B complexes are activated by release 
from inhibitory phosphorylation within the active site. Cyclin B-CDK1 complexes have 
numerous substrates and are known to associate with centrosomes during prophase (180) 
and facilitate in centrosome separation and chromosome condensation (181). At this point 
CDK1 mediated phosphorylation of the origin of recognition complex (ORC) inhibits 
activation of pre-replication complexes (PRC), thus preventing DNA replication until mitosis 
is completed and the nuclear envelope is assembled (182). Rapid degradation B cyclins at 
the onset of anaphase mediates exit from mitosis. The subsequent drop in CDK1 activity 
towards the completion of M phase allows PRC to bind to specific DNA chromosomal sites, 








Figure 1.4. Structure of the cell cycle and regulation of the G1 to S phase transition. The 
cell cycle can be divided into four successive phases. G1 followed by S phase (DNA 
synthesis), G2 and M phase (Mitosis). The G1 to S phase transition is a major restriction 
point (R), once crossed cells are committed to complete the cell cycle. Transition between 
each phase in controlled by specific cyclin-CDK (cyclin dependent kinases) complexes. CDK 
activity is suppressed by two families of inhibitors, the INK family is specific for CDK4 and 







Chapter 1: Introduction 
43 
 
1.3.2 The cell cycle and breast cancer 
Alterations in the mechanisms controlling cell cycle progression are considered a hallmark 
of cancer due to the resulting uncontrolled proliferation. The G1-S phase transition 
encompasses many events that are specifically altered in breast cancer, with dysregulation 
of the cyclin D-CDK4/6-Rb axis occurring in a substantial proportion of breast cancers.  
Loss of pRb function has been described in 20-35% of breast cancers (184). Inactivation of 
Rb protein is more common than deletion or mutation of the RB1 gene. Those cancers with 
loss of pRb function tend to have a more invasive phenotype as Rb inactivation facilitates 
loss of proliferative control and therefore tumour progression (185). In estrogen receptor 
positive breast cancer loss of Rb is associated with poor prognosis (186).  
In cancers with intact Rb, the process of phosphorylating Rb and driving G1 progression 
forward is rate limited by cyclin D. Cyclin D is essential for both normal breast development 
and breast cancer progression (186). Cyclin D is overexpressed in breast cancer either 
through gene amplification or translocations of the CCND locus on chromosome 11q13 
(187). Additionally, signalling via the RAS/RAF/MAPK pathway can increase production of 
cyclin D (188). Over expression of cyclin D is more common than amplification of the 
corresponding gene (189). Amplification of the cyclin D gene (CCND1) has been identified 
in up to 20% of breast cancers (187, 190, 191) and a higher percentage, between 35-40%, 
show overexpression of the protein (192, 193).  
The prognostic implications of cyclin D amplification is currently unclear. CDK4 and cyclin D 
are not required for normal breast cell development, but in mice models CDK4 and cyclin D 
are required for induction of breast tumour growth (194, 195). Some studies suggest cyclin 
D is a dominant oncogene associated with poor outcome (196-198). Specific isoforms of 
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cyclin D might have particular roles. For example, Cyclin D 1a levels have been shown to 
inversely correlate with proliferation and Ki67 levels, however they were not prognostic. 
Whilst, in contrast, cyclin D1b increase was associated with increased recurrence and 
metastases (199).  
Studies suggest Cyclin D might be more specifically associated with ER positive breast 
cancers. As outlined earlier, in ER positive breast cancer cells are dependent on estrogen 
signalling for proliferation and survival, and multiple alterations in cell cycle regulators are 
associated with endocrine resistance. Estrogen can induce cells from G0 to enter the cell 
cycle and increase progression from G1 to S phase (200). Cyclin D is essential for regulation 
of breast epithelial division. ERα directly drives cyclin D transcription and cyclin D can also 
independently activate ERα, driving transcription and cell division (61). Treatment with 
endocrine therapy reduces complex formation of CDKs and cyclins therefore inducing cell 
cycle arrest. Evidence suggests that breast cancer cells that have already developed 
resistance to endocrine therapy remain dependent on cyclin D/CDK4 to promote 
proliferation (201). This suggests a role for CDK4/6-cyclin D signalling in ER independent 
growth of breast cancers.  
Alterations in CDK inhibitors have also been reported in breast cancers. Inactivation of 
CDKN2A, the gene encoding p16, through methylation, gene deletion and point mutation 
has been reported in up to 50% of invasive breast cancers (202). p16 inactivation allows 
uncontrolled cell division and increased proliferation (203). CDKN1B, the gene encoding 
p27, is rarely mutated or deleted, but p27 is frequently reduced in expression or degraded 
by accelerated proteolysis (204-206). Additionally, absence of p27 has been linked to poor 
prognosis in breast cancer (207).  
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The alterations in this checkpoint of the cell cycle in breast cancer suggest it as a good 
target, with a therapeutic role for CDK4/6 inhibitors. 
1.3.3 Targeting the cell cycle for cancer therapy 
Over recent years the cell cycle as a therapeutic target in cancer has been evolving with 
CDKs considered a promising target. Numerous small molecule inhibitors of CDKs have 
been developed. The first generation consisted of pan-CDK inhibitors, with little specificity 
for individual CDKs, such as flavopiridol (Sanofi-Aventis) (208). Whilst, roscovitine 
(Seliciclib, Cyclacel) was initially considered a specific inhibitor of CDK1, 2 and 5, it was later 
discovered to also inhibit CDK7 and CDK9 (209).  
Flavopiridol was the most well studied of these first generation inhibitors. A synthetic 
favone derived from a natural product found in the plant Dysoxylum binectariferum, shown 
to inhibit CDK1,2,4,6,7 and 9 (210). Preclinical evidence showed potent effects in breast 
cancer cell lines. Flavopiridol was shown to induce cell cycle arrest and inhibited cell 
proliferation by 50% at nM concentrations (211). The drug also inhibits angiogenesis, 
induces apoptosis and potentiates the effects of chemotherapy (212, 213). Whilst pre-
clinical studies showed the broad spectrum nature of this drug was promising, this was not 
the case in patients. Phase II clinical trials across different solid tumours; renal cancer 
(214), liver cancer (215), ovarian (216), pancreatic (217) and prostate (218), did not show 
flavopiridol to be particularly effective. In metastatic breast cancer particularly, flavopiridol 
was associated with severe toxicity, especially high rates of neutropenia (219). 
Following from the pan-CDK inhibitors further inhibitors were developed aiming for 
increased selectivity for CDK1 and CDK2. For example, Dinaciclib was specifically developed 
as a potent inhibitor of CDK1,2,5 and 9 (IC50 1-4nM) with less activity for CDK4,6 and 7 (IC50 
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60-100nM) (220). Compared to flavopiridol, dinaciclib exhibited greater activity. In cell 
based assays, dinaciclib suppressed phosphorylation of Rb in over 100 cell lines or multiple 
tumour types and in vivo induced regression of established solid tumours in a range of 
mouse models. However, dinaciclib treatment in combination with chemotherapy in triple 
negative breast cancer was associated with substantial toxicity (221). A randomised trial in 
advanced breast cancer comparing dinaciclib to the chemotherapeutic agent capecitabine, 
was discontinued after only 30 patients had enrolled as interim analysis indicated the time 
to disease progression was inferior with dinaciclib treatment (222).  
The failure of non-selective CDK inhibitors can be attributed to lack of understanding of the 
mechanism of action. With low specificity it is hard to differentiate which CDKs are 
inhibited in pre-clinical models and corresponding to the therapeutic effect. The majority 
of clinical studies were conducted in unstratified patient cohorts. The lack of appropriate 
patient selection and lack of predictive biomarkers to select for the most sensitive patient 
population could contribute to the initial clinical failures. It was thought that specific CDK 
inhibitors might be better suited for cancer with different drivers, such CDK2 inhibition 
might be better to target tumours driven by cyclin E amplification (223, 224). Alternatively, 
specific CDK inhibition might be synergistic with a particular co-treatment, such as CDK1 
inhibitors seem to cooperate with poly(ADP-ribose) polymerase (PARP) inhibitors (223, 
224). This therefore suggested improved selectivity for specific CDKs would be more 
advantageous as a therapeutic strategy. 
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1.3.3.1 Specific CDK4/6 inhibitors 
 
Further understanding of mechanism of CDK4 and CDK6 dysregulation in cancer led to the 
understanding that targeting these CDKs should specifically lead to cytostatic arrest in G1 
phase, and directly suppress Rb initiated gene expression and cell proliferation.  
It was identified that pyrido[2,3-d]pyrimidin-7-one compounds with a 2-aminipyridine side 
chain at the C2 position acted as inhibitors with a high selectivity for CDK4 and CDK6 
compared to other CDKs (225). Subsequent screening and optimisation resulted in the 
compound PD-0332991, now called palbociclib (developed by Pfizer). Drug discovery 
programmes from Novartis and Eli Lilly led to development of LEE011 (Ribociclib) and LY-
2835219 (Abemaciclib) respectively. All three CDK4/6 inhibitors are structurally distinct 
from the un-specific pan-CDK inhibitors. Palbociclib and LEE011 are structurally similar, 
whilst abemaciclib differs in its structure. It is hypothesised these drugs bind to the ATP-
binding pocket of CDK4 and CDK6, with specific interaction with residues within the ATP 
binding cleft (226). Notably, abemaciclib is thought to have a slightly different mechanism 
of action, with a higher selectivity against CDK4 over CDK6 (227). 
Palbociclib is the CDK4/6 inhibitor the most advanced along clinical development. 
Palbociclib is an orally available small-molecule inhibitor of CDK4 and CDK6, with a high 











Figure 1.6 Palbociclib is a small molecule inhibitor of CDK4/6, blocking the phosphorylation 
of Rb inducing cell cycle arrest and preventing cell proliferation.  
 
Figure 1.5. Inhibitory activity of Palbociclib 
against a panel of protein kinases, 
concentration of drug required to inhibit 
50% of activity. Palbociclib is highly 
selective for CDK4/6–cyclin D complexes 
over other targets (1). 
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Treatment at low nanomolar concentrations results in effective G1 arrest though an 
inhibition of Rb phosphorylation in cancer cell lines (228). This inhibition causes 
downstream loss of expression of S phase cyclins, nucleotide biosynthesis, DNA replication 
machinery and cell cycle regulatory genes (229). In vivo a significant anti-tumour effect was 
demonstrated in breast cancer xenografts, with almost complete suppression of tumour 
growth (228). As expected, there is no effect in Rb deficient cells (228, 230). 
Across a panel of breast cancer cell lines, it was observed that ER positive cell lines are 
particularly sensitive to growth inhibition following palbociclib treatment (1). A synergistic 
effect of palbociclib was observed with endocrine therapies in ER positive tumours and cell 
lines. Palbociclib treatment was also able to resensitise tamoxifen resistant cells to 
endocrine therapy. Additionally, it has been shown that resistance to endocrine therapy is 
associated with dysregulation of genes that are controlled by the CDK4/6-pRb-E2F 
pathway. Following from this, CDK4/6 inhibition has been shown to be effective in models 
of acquired resistance to endocrine therapy and treatment is able to induce stable cell 
cycle arrest completely distinct from treatment with ER antagonists (201).  
A phase II study of palbociclib in women with advanced breast cancer showed palbociclib 
treatment was well tolerated and response or prolonged stable disease was demonstrated 
using palbociclib as a single agent (231), whilst a phase I study demonstrated combination 
of palbociclib and letrozole was generally well tolerated and encouraging anti-tumour 
activity was demonstrated (232). Whilst palbociclib is furthest in development, the CDK4/6 
inhibitor from Novartis (LEE011) is also in advanced development, and has been 
demonstrated to be well tolerated in patients with preliminary clinical activity (233). Phase 
II and phase III trials are still ongoing to evaluate LEE011 in combination with endocrine 
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therapy in advanced breast cancer, and also with the addition of the PI3K inhibitor BYL719. 
Abemaciclib has also entered into clinical trials. A small phase I study of solid tumours, 
including 47 breast cancer patients, indicates the potential efficacy of abemaciclib as a 
single agent, with 61% of ER positive breast cancer patients achieving stable disease lasting 
longer than 6 months (234).  
Early trials have defined the key clinical hallmarks upon CDK4/6 inhibition in patients. 
Primarily, neutropenia is the principal dose-limiting toxicity of both palbociclib and LEE011. 
However, this is a reversible effect, indicating the drugs have a cytotoxic effect on 
neutrophil precursors within the bone marrow. To account for this, the drugs have a 
treatment regime with intermittent breaks to allow for haematological recovery (226). 
Abemaciclib has a different toxicity profile, with the dose-limiting toxicity being fatigue, 
allowing for a continuous dosing schedule (234).  
A number of phase II studies have moved forward with combined palbociclib treatment 
with endocrine therapy. The PALOMA-1 trial, a randomised phase II trial in 165 
postmenopausal women with advanced ER positive breast cancer showed significant 
increase in median progression free survival in dual letrozole and palbociclib treatment 
compared to single agent letrozole therapy, 20.2 months compared to 10.2 months 
respectively (235). Subsequently, palbociclib was given Breakthrough Therapy designation 
by the US Food and Drug Administration in April 2015. The further PALOMA-3 trial, a 
double blind phase III trial of 521 breast cancer patients whose cancer had relapsed or 
progressed on prior endocrine therapy, palbociclib combined with fulvestrant improved 
progression free survival from 4.6 months to 9.5 months compared to fulvestrant only 
(236, 237). A longer follow up time is still required to determine the effect of palbociclib on 
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overall patient survival. Another phase III trial (PALOMA-2) is ongoing, to explore the 
efficacy of palbociclib in combination with letrozole for advanced breast cancer, not 
previously treated with hormone therapy.  
Results from trials thus far reveal palbociclib in combination with endocrine therapy to be 
well tolerated and associated with significant and consistently improved progression free 
survival. Development of palbociclib offers a class of treatment for advanced hormone-
receptor positive breast cancer and is likely to be increasingly introduced as standard 
treatment in clinic. However, due to the adaptive nature of cancer, as with endocrine 
therapies, development of resistance to palbociclib can be expected. Therefore with the 
increasing clinical use, acquired resistance to palbociclib is likely to emerge as a new major 
clinical challenge and understanding of resistance mechanisms will become crucial.  
1.4 Krüppel-like Factors  
Krüppel-like factors (KLFs) are a diverse family of homologous genes. All KLFs are DNA 
binding transcriptional regulators that control essential cellular processes including 
proliferation, differentiation, hormone receptor signalling, apoptosis, migration and the 
tumour microenvironment (238).  
Structurally all members of the KLF family have a triple zinc finger domain at the carboxyl 
terminal but the other regions can be highly divergent. Specifically all KLFs contain 
Cys2/His2 zinc fingers, usually encoded by a unique exon situated at the 3’ end of the gene 
(239). It is these highly conserved zinc finger and linker domains that give the KLF 
transcriptional regulatory activity. Several KLFs also share a nuclear localisation signal, 
allowing transport into the nucleus (240). The divergence of the N-terminus allows for 
Chapter 1: Introduction 
52 
 
binding of different co-activators, co-repressors or other factors leading to functional 
diversity of the family. Individual KLFs can be tumour suppressors or oncogenes, often 
context dependent on tissue, tumour type or cancer stage (241). 
1.4.1 Krüppel-like factors in cancer 
The diverse role of KLFs in pathways such as cell proliferation, apoptosis and epithelial-
mesenchymal transition suggest a role for this family of proteins in cancer development, 
growth and metastasis.  
A number of KLFs have been implicated in the dysregulation of proliferation, with cell cycle 
regulators such as the cyclins, CDKs, and CDK inhibitors all common targets for 
transcriptional regulation. For example, in pancreatic cancer KLF4 decrease tumour cell 
proliferation by inducing CDK inhibitors and reducing cyclin D1 expression (242). KLF5 can 
promote cell proliferation in cancer cells by upregulating cyclin A and E2F3, whilst 
decreasing levels of the CDK inhibitors p27 and p15 promoting progression through the 
G1/S phase transition (243, 244). KLF6 is ubiquitously expressed in normal tissues 
controlling cell cycle progression, but expression is lost in many cancers promoting 
proliferation and tumourigenesis (245). Conversely, KLF8 is highly overexpressed in 
ovarian, breast and renal cancer, and can promote cyclin D expression and cell progression 
(246, 247). 
KLFs have been recognised to modulate tumour cell migration and metastasis. KLF8 
promotes EMT and negatively regulates E-cadherin in breast cancer, promoting invasion 
and metastasis (247, 248). Methylation of KLF3 inhibits its expression, which normally 
represses the metastasis inducing miR-182 (249). KLF17 has been documented as a novel 
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tumour suppressor, with reduced expression mediating activation of the TGF-β pathway 
and EMT gene transcription, inducing tumour growth and metastasis (250, 251).  
KLFs also regulate classic apoptotic and cell survival molecules such as BCL-2 family 
members (252). KLF4 is upregulated in breast cancer cells by p53 (253) and promotes 
apoptosis through activation of BAX and downregulation of the pro-apoptotic BCL-2 (254, 
255). KLF5, induces TNFα mediated apoptosis (256). A cooperative effect of KLF5 and KLF4 
has been suggested (257), with knockdown of both required to suppress the anti-apoptotic 
MCL1 (258). KLF9 is expressed during drug induced apoptosis and inhibits tumour cell 
growth through inhibition of AKT activation in prostate cancer (259).  
Additionally, increasing evidence suggests KLFs may have a function in ER signalling. For 
example, estrogen upregulates KLF4 in breast cancer and knockdown of KLF4 inhibits 
estrogen-stimulated growth of breast cancer cells. KLF6 is able to disrupt ERα signalling and 
decrease breast cancer proliferation (260). KLF15 inhibits estrogen induced cell 
proliferation (261). Therefore, KLFs may influence estrogen receptor signalling and 
modulate ERα target gene transcription and thus have a potential to promote or impair 
endocrine-responsive cancers. 
1.4.2 VAV-interacting Krüppel-like factor 
The focus of this PhD is on the role of VAV interacting Krüppel-like factor (VIK-1) in breast 
cancer. VIK-1 is a newly characterised member of the Krüppel-like factor family (Figure 
1.7), which was originally identified in a yeast two-hybrid screen by virtue of its interaction 
with VAV1. 




















Figure 1.7 Phylogenetic tree of Krüppel-like factors. Molecular phylogenetic analysis based 
on the protein sequence showing the relationships of known human KLFs including VIK-1. 
Generated using Clustal Omega (2). 





VAV1 was first identified as a proto-oncogene, whose transforming capacity resulted from 
production of a truncated protein (262). Its isolation led to identification of wild type VAV1 
and subsequent identification of other family members. The VAV proteins are a family of 
signal transduction molecules. The best known function is that of a Rho-guanine nucleotide 
exchange factor (GEFs), although increasing evidence indicates the proteins might have 
other roles. There are currently three known members in mammalian cells VAV1, VAV2, 
and VAV3, all share a similar structure. In addition to the Dbl (DH) and plekstrin-homology  
(PH) typical of Rho GEFs, the proteins contain a calponin-homology (CH) domain, an acidic 
region, a zinc finger domain and two src-homology 3 (SH3) domains flanking a single src-
homology 2 (SH2) region (263). These domains support functional activity beyond just GEF. 
As GEFs, these proteins act as enzymes to catalyse the release of GDP from the inactive 
GTPases, a step that favours the subsequent incorporation of GTP and the acquisition by 
the GTPases of active conformations capable of interacting with effector molecules. VAV 
proteins differ from other GEFs in that their catalytic activity is modulated by direct 
tyrosine phosphorylation (264, 265). It is now thought that the GEF function of VAV 
proteins is highly dependent on the interaction of other adaptor proteins that aid the 
appropriate phosphorylation of VAV (263).  
VAV1 functions as a guanine nucleotide exchange factor for the Rho family of GTPases, and 
plays an important role in T-cell development and signalling, including calcium flux and 
cytoskeletal reorganisation (266). VAV1 is normally exclusively expressed in cells of the 
haematopoietic linage (267), where it is an important mediator of T cell receptor (TCR) 
signalling and is required for development of T cells in the thymus and for their activation 
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and proliferation in response to antigen stimulation (268). Despite this normally restricted 
expression pattern, VAV1 is ectopically expressed in a number of cancers. In a screen of 42 
primary neuroblastomas, 76% expressed VAV1 (269). VAV1 was identified in more than 
50% of pancreatic ductal adenocarcinomas, where VAV1 positive tumours had a worse 
prognosis compared to VAV1 negative tumours (270). VAV1 was also over expressed in up 
to 46% of primary lung cancers (271) and has been correlated with a more aggressive 
tumour behaviour (272). Expression of VAV1 has also been observed in ovarian and 
prostate cancers (273). Whilst aberrant expression of VAV1 is clear in a number of cancers, 
how VAV1 is expressed and the role of ectopic VAV1 in these tissues is uncertain.  
Published data on the role of VAV1 in breast cancer is unclear and sometimes 
contradictory. VAV1 has been reported as overexpressed in 62% of cases (274), whilst 
another group observed VAV1 expression in all but 5 out of 137 breast tumours (275). In 
breast cancer cells lines VAV1 was indicated to have pro-apoptotic role dependent on p53 
(274). However, another study indicated ER mediated upregulation of VAV1 led to 
increased cyclin D levels and cell cycle progression, therefore concluded VAV1 might 
contribute to proliferation of breast cancer cells (276).  
1.4.2.2 Vav-interacting Krüppel-like Factor (VIK-1) 
 
VIK-1 is a splice variant of the ZNF655 gene, located on the long arm of chromosome 7 
(Figure 1.8), with three splice variants as characterised by Houlard et al (277). The best 
characterised isoform is VIK-1, which was shown to be expressed in a variety of tissues. A 
larger isoform known as VIK-2, was only detected in peripheral blood lymphocytes and a 
third smaller isoform known as VIK-3 was weakly detected in all analysed tissues (277). Six 
zinc finger motifs, organised as three tandem repeats within the c-terminal region are 
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conserved between both VIK-1 and VIK-2. These classical zinc finger domains, which can 
bind DNA, RNA and protein, are well conserved between all Krüppel-like factor family 
members. The slightly larger VIK-2 differs only from VIK-1 by an additional KRAB (Krüppel 
associated box) B domain. A VAV1 binding region and CDK4-binding region are also 
conserved between VIK-1 and VIK-2. The smallest isoform, VIK-3 shares only the first 135 
base pairs (Exon 1) with the other isoforms, and contains no zinc finger or KRAB B domains. 
Instead VIK-3 contains a proline-rich domain and a KRAB A domain, not present in VIK-1 or 
-2, and an additional region with no sequence similarity to any known functional domains 
(277). KRAB A and KRAB B domains function as transcriptional repressors (278). Proline rich 
regions are capable of rapid but relatively unspecific binding to substrates and are found in 









Figure 1.8. Schematic representation of the genomic organisation of the 3 alternately 
spliced VIK isoforms. There are 3 isoforms VIK-1 (57kDa), VIK-2 (61kDa) and VIK-3 (20kDa). 
A large CpG island is located upstream of the ATG start site. VIK-1 contains 6 zinc finger 
domains and a separate VAV1 interacting domain and CDK4 interacting domain. These 
domains are conserved within the larger isoform VIK-2, which has an extra KRAB B domain. 
A smaller isoform VIK-3 contains a proline rich domain (Pro), KRAB A domain and an 
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Presently, very little is known about the function of VIK-1. Whilst its structure suggests VIK-
1 has the ability to bind DNA, RNA and protein, only its protein interactions have been 
explored so far in the single published paper regarding VIK-1 (277). In addition to its 
interaction with the c-terminal SH3 domain of VAV1 (amino acids 787-837), the VIK-1 
protein also interacts with CDK4 through another independent domain. Additionally the 
protein is able to shuttle between the cytoplasm and the nucleus, with a limited expression 
within the nucleolus, under the control of a functional nuclear export sequence. VIK-1 is 
variably expressed during the cell cycle, predominantly in the G1 phase. Over-expression of 
VIK-1 blocks cell cycle progression, an effect reversible by expression of VAV1 as co-




Figure 1.9. Schematic representation of the published role of VIK-1 in cell cycle. VIK-1 is 
able to interact with both CDK4 and VAV1. When VIK-1 is over-expressed alone, the cell 
cycle is halted in G1. When VIK-1 is co-expressed with VAV1, cells are able to progress 
through the G1/S phase checkpoint as normal.  
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A methylation array identified VIK-1 as a novel target for epigenetic silencing in breast 
cancer. A genome-wide methylation array was utilised to identify aberrant methylated 
regions across breast cancer cell lines, to determine potential genes that could be 
regulated by transcriptional silencing via epigenetic means. Preliminary results from our lab 
showed that in a cohort of ER positive breast cancer patient samples, VIK-1 methylation 
was associated with increased risk of recurrence in tamoxifen-treated patients. VIK-1 
methylation was additionally associated with poor outcome in patients treated with 
tamoxifen. There was a strong trend observed towards shorter survival in methylated 
patients, independently of ER, tumour size or grading  (Figure 1.10) (280). This led to the 
hypothesis that VIK-1 may have a role in estrogen receptor positive breast cancer and VIK-1 
methylation could be a marker for poor prognosis in breast cancer. This, combined with 
the functional role in cell cycle regulation, suggested the role of VIK in breast cancer 


















Figure 1.10. Methylation of VIK-1 and patient outcome. Kaplan-Meier curve for overall survival 
in a panel of 226 patients with stage I-III primary breast cancer treated with adjuvant 
tamoxifen with respect to VIK-1 methylation status. Figure from Crook et al (unpublished 
data). 
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2 Aims and Objectives 
Confirm the epigenetic regulation of VIK-1 in breast cancer  
Preliminary data identified VIK-1 as a novel potential target for epigenetic silencing in 
breast cancer cells. The first aim of this PhD was to confirm the whether methylation-
dependent transcriptional silencing is a mechanistic basis for VIK-1 down-regulation and to 
identify the importance of this epigenetic silencing in breast cancer. Further to this, a 
preliminary patient cohort linked methylation of VIK-1 to patient survival. Therefore, this 
PhD aimed to further determine VIK-1 expression and methylation in primary breast cancer 
samples, and confirm the significance of VIK-1 methylation on patient outcome.  
 
Examine the functional role of VIK-1 in estrogen receptor positive breast cancer and 
potential role in endocrine resistance 
Krüppel-like factors have been previously linked to estrogen receptor signalling. The 
preliminary breast cancer cohort suggested differential outcome in patients receiving 
endocrine therapy with regards to VIK-1 levels and methylation. Additionally, there was an 
increased risk of recurrence following tamoxifen treatment. This particularly indicated a 
role for VIK-1 in estrogen receptor positive breast cancer, and potentially a role in 
resistance to endocrine therapy. Therefore, the second aim of this PhD was to investigate 
the potential for VIK as a determinant of sensitivity to endocrine therapy and examine the 
functional consequences of modulating VIK expression within ER positive breast cancer.  
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Investigate the role of VIK-1 within the cell cycle with regards to its interaction with 
VAV1 and CDK4 
VIK has been suggested to play a role in cell cycle progression, interacting with CDK4 and 
VAV1. VIK-1 has been shown to inhibit cell cycle progression through G1 to S phase, an 
inhibition that might be reversed by presence of VAV1. Therefore, the aim was to 
investigate, in breast cancer, the role of VIK-1 on cell cycle progression and effect on 
proteins involved in G1/S phase transition. In addition, to elucidate the interaction of VIK-1 
and VAV1. Furthermore, the interaction with CDK4 could suggest VIK-1 as a determinant of 
sensitivity to CDK4/6 inhibitors. The final aim of this PhD was to investigate any potential 
relationship between VIK-1 and sensitivity to palbocicilib, a specific CDK4/6 inhibitor.  
 
 
    
 64 















Chapter 3: Materials and Methods 
65 
 
3.1 Cell Culture Assays 
3.1.1 Cell Culture and reagents 
A panel of breast cancer cell lines was selected from a variety of disease states. All cells 
were grown in a 5% CO2 humidified atmosphere at 37°C, in cell culture media (base media 
indicated in Table 3.1). Unless otherwise stated baseline media was supplemented with 
2mM L-glutamine and 10% foetal bovine serum (FBS). MLET5 and LCC9 were 
supplemented with 2nM L-glutamine 10% double stripped serum (DSS). MCF10A media 
was supplemented with 5% horse serum (Invitrogen), 2mM L-glutamine 20ng/ml, EGF 
(Sigma), 0.5mg/ml hydrocortisone (Sigma), 100ng/ml cholera toxin (Sigma) and 10μg/ml 
insulin (Sigma).  
 
All cells were adherent monolayer human cell lines. Cells were passaged through 
trypsination. Media was removed and cells washed with PBS. 1x trypsin-EDTA was added 
and cells incubated at 37°C, until cells had visibly detached. Appropriate media 
supplemented with FCS, which contains trypsin inhibitors, was added to at least 3 times 












Table 3.1: Panel of breast cancer cell lines. The panel of cell lines covered a wide range of breast 
cancer subtypes with varying tumour origin. Subtype is determined by positive (+) or negative (-) 





Cell Line Media Tumour origin Subtype ER PR HER
2 BT549 RPMI 1640 invasive ductal carcinoma Triple negative, basal  - - - 
MDA-MB-231 DMEM adenocarcinoma Triple negative, basal  - - - 
MDA-MB-436 DMEM adenocarcinoma Triple negative, basal  - - - 
Hs578T DMEM  Triple negative, basal  - - - 
MDA-MB-468 DMEM adenocarcinoma Triple negative, basal  - - - 
Hcc1937 RPMI 1640 primary ductal carcinoma Triple negative, basal  - - - 
MDA-MB-453 DMEM metastatic luminal Triple negative - - - 
T47D RPMI 1640 ductal carcinoma ER positive, luminal A + + - 
MCF7 RPMI 1640 adenocarcinoma ER positive, luminal A + + - 
MLET5 DMEM-phenol red MCF7-derived,  
ectoposide resistant 
ER positive, luminal A + + - 
LCC9 DMEM-phenol red MCF7-derived, 
fulvestrant resistant 
ER positive, luminal A + + - 
SUM44 DMEM + 500nM 
E2 
 ER positive, luminal A + - - 
ZR751 RPMI 1640 ductal carcinoma ER positive, luminal A + - - 
MDA-MB-361 Leibovitz's L-15 adenocarcinoma HER2 positive, luminal 
B 
+ - + 
SKBR3 McCoys adenocarcinoma HER2 positive, basal - - + 
JIMT1 DMEM ductal carcinoma HER2 positive, basal  -  + 
BT474 DMEM invasive ductal carcinoma HER2 positive, luminal 
B 
- + + 
Hcc1569 RPMI 1640 primary metastatic 
carcinoma 
HER2 positive, basal  - - + 
Hcc1954 RPMI 1640 ductal carcinoma HER2 positive, basal  - - + 
MCF10A DMEM F12 normal breast epithelium  - - - 
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3.1.2 siRNA knockdown 
Cells were reverse transfected with gene targeting siRNA (Dharmacon, table 3.2) or a 
scrambled non-targeting control (Allstars negative control siRNA, Quiagen) and 
Lipofectomine (Life Technologies). siRNA was added to the well followed by lipofectamine 
(both prepared in serum free media). Complexes were formed with a lipofectamine:siRNA 
ratio of either 15:1 with 20nM siRNA (T47D, MCF7, MCF10A) or 6.25:1 with 80nM siRNA 
(SUM44). Plates were incubated at room temperature for 20 min for complexes to form 
before cells were seeded. 24 hours after transfection the media was changed. Transfected 
cells were then used for assays as described below, or washed in PBS and cells collected for 
RNA and protein isolation. 





3.1.3 Vector expression of VIK-1 
Cells were seeded to 60% confluency. Complexes of VIK-1 expression vector (PCDNA3.1-
VIK-1 or pEGFP-VIK-1) or corresponding empty vector containing no insert with 
Xtremegene reagent (Roche), at a ratio of 1:2, were incubated for 20 minutes at room 
temperature before addition to the cells. Cells were either transiently transfected for 72 
hours or plasmid expressing cells were selected by growth of drug resistant colonies with 
G418 (Sigma), either 200µg/ml for MCF7 and MLET5 or 300µg/ml for LCC9. A kill curve was 
Target Gene Target Sequence 
VIK siRNA 1 CCGACAUGGAACAGGGACU 
VIK siRNA 2 CACCAAGGGUCCAGUUUCA 
VIK siRNA 3 AGGAAAUACCAGCCCAGGA 
VAV1 CGACAAAGCUCUACUCAUC 
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carried out to determine concentration of G418 and the IC50 concentration at day 5 of drug 
treatment were used.  
3.1.4 MTT cytotoxicity assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT, Alpha Aesar) was 
dissolved in supplemented media at a stock concentration of 2mg/ml. At the indicated 
time points, MTT assay was added at a 1:3 dilution, directly to the cell culture well 
(0.66mg/ml final concentration) and cells incubated for 1.5-3 hours at 37°C. The media was 
then removed and DMSO added to solubilise the dye (100 µl in a 96 well plate) Optical 
density (OD) was read at 570nm and 650nm (Perkin-Elmer 1420 Plate reader). The 650nm 
reading was subtracted from 570nm to account for background. 
For IC50 assays, cells were seeded or transfected and allowed to adhere for 24 hours then 
treated with varying concentrations (0.005µM-10µM) of palbociclib (SelleckChem) or 
DMSO vehicle control as indicated for 6 days. Values were normalised to the vehicle 
control and IC50 determined using GraphPad Prism (GraphPad software). Briefly, drug 
concentrations were Log10 transformed and plotted against the normalised OD value. Non-
linear regression for normalised dose-response inhibition was applied to calculate IC50 
values. Experiments were performed in triplicate and a representative IC50 curve is 
presented as average of technical triplicates ±SD.  
3.1.5 Estradiol stimulation 
Cells were seeded and after 24 hours cells were washed 3 times with PBS and media 
replaced with RPMI 1640 without phenol red plus 10% double stripped serum (DSS) for 72 
hours before addition of 1nM β-estradiol (E2, Sigma) or equivalent concentration of 
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ethanol vehicle control. Cells were collected following treatment for RNA or protein 
analysis. 
3.1.6 TGF-β and EGF stimulation 
Cells were seeded and allowed to adhere overnight. 10ng/ml TGF-β (Sigma), 40ng/ml EGF 
(Sigma) or vehicle control was added directly into the cell culture media and incubated at 
37°C for the indicated time point.  
3.1.7 Hypoxia 
For hypoxic treatment cells were exposed to 1% oxygen, 5% CO2, within a Ruskinn Invivo2 
400 hypoxic workstation, for either 24 or 48 hours. The chamber was humidified and 
maintained at 37°C.  
3.2 Generation of palbociclib resistant cell lines 
Drug resistant variants of each cell line were derived from the original parental cell line 
through continuous exposure to pabociclib. Following initial dose-response studies over a 
range of palbociclib doses (0.1nM-10µM), IC50 values were determined. T47D and MCF7 
cell lines were cultured in increasing concentrations of pablociclib starting with 200nM, 
approximately the IC50 value. Drug sensitive cells died and the remaining live cells were 
cultured in this dose until cells were outgrowing the dose. At this point the drug 
concentration was increased. This was continued over a period of 6 months, gradually 
increasing the drug concentration to 1µM.  Individual clones were selected from each cell 
line and MTT assays were performed to determine IC50 values. Three clones of each cell 
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line exhibiting drug resistance were continued. Resistant clones were then maintained with 
1µM palbociclib in the culture media.  
3.3 Quantitative Real Time PCR   
3.3.1 RNA extraction and preparation of cDNA 
Total RNA was extracted using a phenol based extraction protocol. TriReagent (Sigma) was 
added to cells and homogenised. 1-bromo-3-chloro-propane (Sigma) was added at 1 in 10 
dilution, cells were vortexed then centrifuged for 10min at 12,000rpm 4°C. The aqueous 
phase top layer was transferred into a new tube and an equal volume of propan-2-ol 
added. Following vortexing and a 10 minute incubation at room temperature, the sample 
was centrifuged at 12,000rpm for 5 minutes to pellet the RNA. The supernatant was 
removed and 75% ethanol added. The sample was centrifuged at 12,000rpm for 5 minutes, 
the supernatant was removed and air-dried before the pellet was resuspended in RNAse 
free water. The RNA was quantified using a spectrophotometer (Nanodrop ND-1000).  
100ng of RNA was reverse transcribed using Multiscribe Reverse Transcriptase (Applied 
Biosystems High Capacity Reverse Transcriptase cDNA kit) as per manufacturer’s 
instructions, incubating at: 25°C 25 minutes, 37°C 120 minutes, 85°C 5 minutes (Applied 
Biosystems 7500 thermal cycler).  
 
3.3.2 TaqMan quantitative PCR 
Quantitative real time PCR for total VIK and VAV1 was carried out using individual TaqMan 
gene expression assays (Life Technologies) and TaqMan Universal PCR Master Mix (Life 
Technologies) to determine expression of each gene. RPLPO was used as a reference gene 
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to which VIK-1 and VAV1 expression was relatively calculated. Cycling conditions were as 
follows: Initially 95°C for 10 min, then 95°C 15 seconds, 60°C 1 minute for 40 cycles using a 
Stratagene Mx300P QPCR System (Agilent Technologies). CT values were determined at the 
intersection of the amplification curve and a threshold line set at 0.1 for all experiments. 
The average CT was taken of technical duplicates. For data analysis the comparative CT 
method was used (281). CT values for RPLPO were subtracted from gene of interest values, 
giving a ΔCT value. Fold difference was calculated using the formula: 2^(-ΔCT), giving the 
RNA expression of the gene of interest relative to RPLPO. Standard deviation was 
calculated for each data set as outlined in the Applied Biosystems guide to performing 
relative quantitative gene expression.  
 
3.3.3 SYBR Green quantitative PCR 
For each VIK isoform SYBR Green assays were utilised (Table 3.2). Primers were designed 
using Primer3 software (www.primer3.ut.ee). PCR reactions were carried out with a final 
volume of 10µl, using 500nM of each primer and 2ng of cDNA, and 2x SYBR Green PCR 
master mix (Life Technologies). Cycling parameters were as above, followed by melt curve 
acquisition. ΔCT and fold change were calculated as above. Due to the sequence similarity 
of VIK-1 and VIK-2 it was not possible to design primers to solely detect VIK-1, so VIK-1 
expression was determined by subtraction of VIK-2 expression from total VIK-1+VIK-2 
expression. A standard curve of cDNA for each primer pair was performed and efficiency 
calculated from the slope (efficiency=-1+10(-1/slope)) (282). A slope between -3.1 and -3.6, 
corresponding to an efficiency of 90-110%, is generally considered acceptable. All SYBR 
Green primers had an efficiency within the acceptable range (Figure 3.1). 
 




Figure 3.1. Efficiency of SYBR Green primers. A standard curve was performed for each 
primer pair and primer efficiency was calculated from the slope of the curve where 
efficiency=-1+10(-1/slope). 
Table 3.3. SYBR Green qPCR primers. Primer pairs were designed to amplify each isoform 
of VIK, or the housekeeping gene RPLPO.  
 
Gene Forward Primer Reverse Primer Slope Primer 
efficiency 
VIK-1 + VIK-2 TGAATGTCATGAACCCGAAA GGTGGGAGAGATCCATTAAGC -3.248 103% 
VIK-2 ACTGGGGGATTTCCAATTTC CTGGTCTCTCCATCTGAGCA -3.368 98% 
VIK-3 CAGGAGTTTGTGACATTCG AGAAGTATGCCCAGTCAG -3.254 103% 
RPLPO GCGACCTGGAAGTCCAACTA GGATCTGCTGCATCTGCTTG -3.254 103% 
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3.4 RNA sequencing 
RNA was extracted using RNeasy Qiagen kit. The BCI genome centre prepared the RNAseq 
library (polyA mRNA) sequenced the libraries using paired-end Illumina NextSeq 500 high 
output Run (150 cycles). TopHat (version 2.0.9) was used to align paired end reads to the 
human genome (hg19) (283). HTSeq package (version 0.6.1p1) was used to count the 
overlap of reads with genes using GENCODE version 19 human gene annotation (284). The 
read count data was filtered to keep genes that achieved at least one read count per 
million in at least three samples. Reads per kilobase per million mapped reads (RPKM) 
values were calculated with the conditional quantile normalisation (cqn) counting for gene 
length and GC content, using the R statistical environment via Bioconductor packages.  
3.4.1 Differential expression analysis 
LIMMA (linear models for microarray data) was applied to fit a linear model to RPKM 
values for each gene to determine genes that were differentially expressed between 
sensitive and resistant groups. Differentially expressed genes were evaluated using LIMMA 
empirical Bayes statistics module (285). The adjusted p-values (false discovery rate) was 
estimated by the Benjamini and Hochberg procedure (286). The differentially expressed 
genes were selected when the adjusted p-value was less than 0.05 and the absolute value 
of log-fold change was more than 1. Bioinformatic analysis was carried out by the 
bioinformatics group at BCI.  
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3.5 Protein Analysis 
3.5.1 Cell lysis and quantification 
Cells were washed in ice cold PBS and lysed in ice cold RIPA buffer (150 mM sodium 
chloride, 1.0% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulphate, 50 mM Tris, pH 8.0) with protease inhibitor (cOmplete mini Protease Inhibitor, 
Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail, Sigma) shaking for 20 
minutes at 4°C. Lysates were centrifuged 10,000rpm, 4°C for 10 minutes and the 
supernatant removed into a fresh tube.  
 
Protein was quantified using Pierce BCA protein Assay Kit (Life Technologies). 5µl of bovine 
serum albumin protein standards ranging from 0.125-2mg/ml were added to a 96 well 
plate in duplicate and 1µl of sample protein lysates. Reagents A was added to Reagent B at 
a 1 in 50 dilution and then 200µl was added per well. The plate was incubated at 37°C for 
30 minutes and read at 750nm on a plate reader (Perkin Elmer). Protein concentrations 
were calculated by comparison to the protein standard curve. Lysates were diluted in 2x 
Laemmli buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, 0.125M Tris HCl, pH6.8) 
plus 10% β-mercaptoethanol (Sigma), then denatured at 90°C for 10 minutes. 
 
3.5.2 Western Blot 
20-40µg of protein was resolved by SDS-page electrophoresis on a 10% acrylamide gel, run 
at 150 volts for 1 hour in standard running buffer (Tris Glycine SDS, Severn Biotech) in a 
Mini Trans Blot system (Bio-Rad). Proteins were transferred onto a PDVF membrane (GE 
Healthcare) activated in methanol using a wet transfer conditions for 1 hour at 300mA in 
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transfer buffer (Tris Glycine, Severn Biotech, plus 20% Methanol).  Membranes were 
blocked in 5% non-fat milk in PBS-T (1x TBS with 0.001% Tween) for 1 hour, or 5% BSA-TBS-
T (1x PBS with 0.001% Tween) for pRb, shaking at room temperature. Membranes were 
incubated in primary antibody (Table 3.4) diluted in blocking buffer, shaking overnight at 
4°C. After 3 times 10 minute washes in PBS-T, membranes were incubated in secondary 
antibody at room temperature for 45 minutes. Membranes were washed 3 times again in 
PBS-T and visualised using ECL Plus (BioRad) using SynGene G:Box system. Densitometry 
quantification of western blots was performed using the gel analysis tool from ImageJ 
software. Density of each band was determined and normalised to density of the β-actin 
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Protein Dilution Host Species Company 
β-Actin 1:5000 Rabbit Cell Signalling #4970 
VIK 1:750 Rabbit Custom made (Eurogentech) 
VIK 1:15000 Rabbit Abnova PAB22301 
VIK 1:2000 Rabbit Aviva ARP39587 
CDK4 1:1000 Rabbit Cell Signalling #12790 
Cyclin D 1:500 Rabbit Santa Cruz sc-753 
Rb 1:1000 Mouse Cell Signalling #9309 
pRb s780 1:1000 Rabbit Cell Signalling #9307 
Cyclin E 1:200 Mouse Santa Cruz sc-56310 
CDK1 1:1000 Mouse Abcam ab18 
CDK2 1:500 Mouse Santa Cruz sc-6248 
E2F1 1:200 Mouse Santa Cruz sc-251 
p27 1:100 Mouse Santa Cruz sc-56338 
Full length PARP 1:1000 Rabbit Cell Signalling #9542 
Cleaved PARP 1:1000 Rabbit Cell Signalling #9661 
GFP 1:1000 Mouse Roche  11814460001 
Rabbit 1:2000 Goat Cell Signalling #7074 
Mouse 1:2000 Goat Cell Signalling #7076 
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3.5.3 Immunoprecipitation  
Cell were first transfected with pEGFP tagged VIK expressing vector, or empty pEGFP vector 
as described above, for 48 hours. A master mix of 2% BSA/PBS and 2µg of antibody either 
GFP or Mouse IgG control, was prepared for each reaction. 2µg of antibody was conjugated 
to 35µl of protein A agarose beads (Millipore) overnight at 4°C with rotation. After 3 
washes in ice cold PBS, cells were lysed in RIPA + protease and phosphatase inhibitors. To 
inhibit any proteasome degradation of VIK protein, 10µM MG132 was added to media for 2 
hours prior to cell lysis, and also to the RIPA lysis buffer. Cells were kept on ice and 
vortexed 3 times, then centrifuged for 14,000rpm for 10 minutes at 4°C. 50µl of the 
supernatant was saved for input and the remainder used in the IP. Following antibody 
conjugation, the beads were centrifuged at 3,500rpm for 1 minute. The protein lysate was 
transferred to the beads and incubated for 4 hours at 4°C with rotation. Beads were 
washed 3 times with 75:25 RIPA:PBS, then once with PBS. 35ul of 2x Laemmlli sample 
buffer was added to the beads and sample boiled for 5 minutes at 95°C. Samples were 
resolved by SDS-page and blotted as described above.  
3.5.4 Coomassie Blue staining 
Proteins were resolved on an agarose gel as describe above. The gel was rinsed with 
distilled water then fixed in 50% methanol, 10% acetic acid for 1 hour. The gel was rinsed 
with distilled water then incubated in staining solution (0.1% coomassie brilliant blue, 50% 
methanol, 10% acetic acid) for 2 hours with gentle agitation. The gel was destained in 
destaining solution (40% methanol, 10% acetic acid) for 2 hours with gentle agitation, and 
replacement of destaining solution several times, until the background of the gel was fully 
destained. The protein band was cut out from the gel and frozen before mass spectrometry 
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analysis. Mass spectrometry analysis was carried out by the Barts Cancer Institute mass 
spectrometry laboratory.  
3.5.5 Immunofluorescence 
Cells were seeded onto sterile glass coverslips in a 6 well plate and incubated as normal for 
3 days. Media was aspirated and wells washed in PBS. Cells were fixed in 4% 
paraformaldehyde (PFA) for 1 hour at room temperature. After washing in PBS cells were 
permeabilised in 0.2% triton-X in PBS for 10 minutes at room temperature. Cells were 
blocked in 1% BSA, 2% FCS in PBS for 30 minutes at room temperature. Cells were 
incubated with custom Rabbit anti-VIK antibody 1:1000 dilution in blocking buffer, or 
blocking buffer alone for a secondary only control, overnight at 4°C. After 3 washes, each 
for 5 minutes, cells were incubated in 1:1000 dilution of secondary antibody (Goat anti 
Rabbit Alexa Flour 488, Thermo Fisher Scientific), in the dark at room temperature for 45 
minutes. Cells were again washed 3 times in PBS, and mounted onto glass microscopy 
slides using anti-fade fluoromount aqueous mounting medium (Sigma) containing a 
1:10000 dilution of DAPI (4',6-diamidino-2-phenylindole). 3D image stacks were acquired 
on an Olympus DeltaVision microscope (Applied Precision) in 0.2µm steps, using the 
Olympus X40 oil objective. 
3.6 Methylation analysis 
3.6.1 DNA extraction from cell lines 
Genomic DNA was extracted from cell lines using GenElute blood genomic DNA extraction 
kit (Sigma). Cells were resuspended in 200µl PBS and added to 10μl of Proteinase K (to 
digest proteins), then 200µl of resuspension solution added. Cells were lysed by addition of 
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200µl of Lysis solution C and incubation at 55°C for 10 minutes. 500µl of column 
preparation solution was added to each column, and centrifuged 12,000rpm for 1 minute, 
to maximise binding of DNA to the column. To prepare the DNA for binding 200µl absolute 
ethanol was added to each lysate and thoroughly vortexed, before transfer to the prepared 
column. Samples were twice washed with Wash Solution and centrifuged for an additional 
minute to remove any residual ethanol. 200µl of elution solution was added to the column 
for 5 minutes at room temperature then centrifuged for 1 minute to elute DNA. 
DNA was quantified using a spectrophotometer (Nanodrop ND-1000). The ratio of 
absorbance at 260nm and 280nm was used to assess the purity of the DNA, with a ratio of 
1.8 accepted as ‘pure’ DNA.  
3.6.2 DNA extraction from primary breast cancer tissue samples 
DNA was extracted from FFPE embedded tissue on uncharged slides. Paraffin was first 
removed by immersing the slides twice in xylene for 10 seconds, followed by 2 times 10 
second washes in ethanol. The slides were air dried to allow ethanol evaporation, and 
tumour sections were scraped off in lysis buffer with a sterile scalpel and placed into 
eppendorf tubes. DNA was extracted from FFPE primary breast cancer samples using 
Allprep DNA/RNA FFPE kit (Qiagen), as per the manufacturer’s instructions. Briefly, the 
tissue was lysed in the presence of proteinase K for 15 minutes at 56°C. Following 3 
minutes incubation on ice, samples were centrifuged at 12,000rpm at room temperature. 
The pellet is further lysed in the presence of proteinase K at 90°C for 2 hours. The genomic 
DNA was resuspended in buffer AL with ethanol and applied to the mini elute spin column. 
The DNA was bound to the silica membrane and washed with buffer AW1 and AW2 
followed by ethanol to remove contaminants. DNA was eluted in 50µl of buffer TE.  
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A standard curve of bacteriophage lambda DNA was prepared in TE buffer ranging from 
2.5ng/µl to 25pg/µl. In a 96 well plate 1µl of DNA was diluted in 50µl working PicoGreen 
solution (Life Technologies). The plate was incubated at room temperature for 5 minutes 
protected from light. The fluorescence was read at 520nm (Perkin Elmer Plate Reader) and 
DNA concentration calculated from the standard curve.  
3.6.3 Bisulphite conversion 
DNA was bisulphite converted, where unmethylated cytosine residues are converted to 
uracil by addition of a bisulphite group. Bisulphate modification was carried out using an EZ 
DNA methylation kit (ZymoResearch) following manufacturer’s instructions, using 500ng 
DNA extracted from cell lines. The kit is based on the three-step reaction between an 
unmethylated cytosine and sodium bisulphite (Figure 3.2). Therefore the converted DNA 
sequence reflects the methylation status. 500ng of DNA was diluted to 45µl in molecular 
grade water, 5µl of M-dilution buffer was added. Samples were incubated at 37°C for 15 
minutes. 100µl of CT conversion reagent was added to each sample, samples were 
incubated in the dark at 50°C overnight, where unmethylated cytosines were converted to 
uracils. Samples were incubated on ice for 10 minutes, and then added to 400µl of M-
binding buffer preloaded into the Zymo-spin column. Following centrifugation at 
12,000rpm for 30 seconds, 100µl of M-wash buffer was added. Columns were again 
centrifuged, then 200µl of desulphonation buffer added, samples were incubated at room 
temperature for 15 minutes to desulphonate the DNA. This was followed by 2 washes with 
M-wash buffer. DNA was eluted in 50µl of M-elution buffer.  




Figure 3.2. Bisulphite conversion of cytosine to uracil. Step 1, unmethylated cytosines are 
protonated. Bisulphite (HSO3) treatment transforms the protonated cytosine into cytosine 
sulphonate. Step 2, overnight incubation produces uracil sulphonate. Step 3, deamination 
and following desulphonation forms uracil. Only unmethylated cytosines will react with 
bisulphite, forming uracil. Cytosines methylated at the 5th carbon position will not, thereby 








100ng of bisulphite converted DNA was amplified by PCR using Pyromark PCR kit (Qiagen) 
using the following conditions: 95°C for 10 min, then 40 cycles of 94°C 30 seconds, 54°C 30 
seconds, 72°C 30 seconds followed by 72°C for 10 min. 0.5µM of primers was used in a final 
reaction volume of 30µl (forward primer GGGTAAGGTTTTTTGAGGA-5’BIOT, reverse primer 
CCACTTTTAAAATCAAACCCT). The PCR product was then used as the template for 
pyrosequencing using the PyroMark Q96 Vacuum Prep workstation (Qiagen). The 
biotinylated PCR product was bound to streptavidin coated sepharose beads, then 
immobilised, washed, denatured and annealed to the non biotinylated sequencing primer 
at 80°C for 2 minutes. Commercially available methylated DNA was used as a positive 
control and placenta DNA used as a negative control. In pyrosequencing the DNA sequence 
is determined by light emitted upon incorporation of complementary nucleotides. The 
proportion of methylation at each CpG can be quantified based on the ratio of C to T 
nucleotides incorporated. Methylation values were calculated as average methylation over 
8 CpG sites.  
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For primary breast cancer samples 100-500 ng of DNA was sent to the Barts Cancer 
Institute Genome Centre (Queen Mary, University of London) for pyrosequencing using 
their standard protocols. 
 
Figure 3.3. Representative pyrogram generated by the Pyro Q-CpG software (Qiagen) 
showing the methylation levels of 8 CpG dinucleotides. The x-axis shows the nucleotide 
dispensation and peaks represent emission following nucleotide incorporation. The ratio of 
C to T is automatically calculated by the software at each CpG site.  
 
3.6.5 Methylation Reversal Assays 
Cells were grown until 60% confluent. Media was replaced, and 5µM 5-aza-deoxycytidine 
(AZA) (Sigma) was added and incubated for 5 days. For the final 16 hours before harvest 
0.3nM Trichostatin (TSA) (Sigma) was added to the media. On day 5, cells were washed 
with PBS, removed from the flask with trypsin, pelleted and stored at -20°C for DNA, RNA 
or protein extraction.  
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3.6.6 450K methylation array 
Breast cancer cell lines were profiled using the Infinium Human Methylation 450 BeadChip 
(Illumina). 1µg genomic DNA was extracted from cell lines as described and sent to the 
Genome Centre, Barts Cancer Institute London, for microarray hybridisation, scanning 
(Illunmina iScan system) and quality control according to standard operating procedures. 
The scanned data were first normalised to reduce the differences between the two types 
of probes within the array. Infinium I probes are designed across the CpG dinucleotide, 
meaning there are two probes for each, whilst as the Infinium II are designed immediately 
adjacent to the CpG so there is only one probe. After normalisation methylation status of 
each CpG site was presented as β-values (the ratio of methylated signal to the total signal). 
3.7 Preparation of VIK-1 expressing plasmids 
3.7.1 Amplification of pcDNA3.1-VIK vector 
A pcDNA3.1 vector containing the full-length coding region of VIK-1 (Figure 3.4) was gifted 
from Nadine Varin-Blank (Departement d'Hematologie, Institut Cochin, Paris, France). To 
amplify the plasmid, DNA was transformed into DH5α chemically competent E.coli cells 
(NEB). Cells were thawed on ice and 5ng of DNA added to 50µl of cells. Cells were 
incubated on ice for 30 minutes followed by heat shock for 45 seconds at 42°C, then placed 
on ice for 5 minutes. 350µl of S.O.C (super optimal broth with catabolite repression) 
medium was added and cells incubated at 37°C, shaking at 225rpm for 1 hour. 50µl were 
plated onto Luria-Bertani (LB) agar plates with 100µg/ml ampicillin. Multiple single colonies 
were picked from plates and grown overnight in LB broth plus ampicillin. Plasmids were 
purified from cell cultures using QIAprep Spin Miniprep Kit (Qiagen). DNA was confirmed 
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by running on 1% agarose gel with gel red (Biotium) alongside a 1kb ladder (NEB) in Tris 
Borate EDTA (TBE) for 1 hour at 100V. Sequences were confirmed by sequencing (GATC 
Biotech). Selected colonies were further grown up in 300ml LB broth and purified using the 












Figure 3.4. Diagrammatic representation of the pcDNA3.1-VIK-1 plasmid. The plasmid 
contains a cytomegalovirus (CMV) promoter for high level stable expression. The gene of 
interest, VIK-1, sequence has been cloned into the multiple cloning site (MCS). A neomycin 
resistance cassette allows for selection using G418 in mammalian cells and ampicillin 
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3.7.2 Cloning into pEGFP vector 
VIK-1 gene sequence was amplified from the PCDNA3.1 expression vector and cloned into 
a pEGFP vector (Figure 3.5). PCR primers were designed with restriction site at the 5’ end 
of the primer: 
Forward Primer: ACGAATCTCGAGATGGAGGAAATACCAGC  
Reverse primer: ACCAAAGAGAACTCATGAGGTACCACGAAT 
Amplification was carried out with Phusion High-Fidelity DNA polymerase (NEB). 5ng of 
DNA was amplified, with 0.5µM forward primer, 0.5µM reverse primer in a 25µl final 
reaction volume. Cycling conditions as follows; an initial denaturation step of 98°C for 30 
seconds, followed by 25 cycles of: 98°C for 10 seconds, 72°C annealing for 10 seconds, 72°C 
for 38 seconds (25 seconds/kb for 1.5kb sequence), then a final extension of 72°C for 2 
minutes. The PCR product was purified using PCR purification kit (Qiagen). The insert and 
pEGFP vector were digested with restriction enzymes in Cutsmart buffer (NEB) for 2 hours 
at 37°C. DNA was run on a 1% agarose gel and DNA extracted from the gel (Qiagen DNA gel 
extraction kit). 95ng of VIK-1 Insert was ligated into 100ng pEGFP vector (molar ratio 3:1) 
using instant sticky-end ligase master mix (NEB), an equal volume of DNA and 2x master 
mix was incubated for 10 minutes at room temperature.  
The ligated plasmid was transformed into DH5α chemically competent E.coli cells (NEB) as 
described above. Successful cloning of VIK-1 insert into the pEGFP vector was confirmed by 
a diagnostic digest with the restriction enzymes and sequencing (GATC). 
3.7.3 Site directed mutagenesis for deletion of small DNA sequence  
After cloning a small DNA sequence between the end of the GFP sequence and the 
beginning of the VIK-1 had to be removed for the VIK-1 sequence to be in frame. Site 
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directed mutagenesis was utilised to delete the small linker DNA sequence. A standard 
forward primer was designed at the end of the section to be deleted, and a reverse primer 
from the beginning of the region to be deleted. Following PCR the DNA section is not 
amplified, and therefore deleted (Forward Primer: GAGGAAATACCAGCCCAG, Reverse 
Primer: CTTGTACAGCTCGTCCATG). 
PCR was carried out using Phusion polymerase as described above. The PCR product is a 
linear sequence of the DNA including the insertion. This was followed by incubation with a 
kinase, a ligase and DpnI (KLD) for circularisation of the PCR product. 1µl was incubated 
with 5µl of 2x KLD reaction buffer, 1µl of 10x KLD enzyme mix, the reaction was incubated 
for 5 minutes at room temperature then transformed into E.coli cells, colonies selected and 




















Figure 3.5. Diagrammatic representation of the pEGFP-VIK-1 plasmid. The plasmid 
contains a cytomegalovirus (CMV) promoter for high level stable expression. The gene of 
interest, VIK-1, sequence has been cloned into the multiple cloning site. EGFP is located at 
the N-terminal of VIK-1. A neomycin resistance cassette allows for selection using G418 in 
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3.8 Flow Cytometry Analysis 
3.8.1 DNA staining for cell cycle profile 
Cell cycle analysis was performed by quantification of DNA content using the DNA binding 
dye DAPI. The stage of the cell cycle can be measured by the relative DNA content of each 
cell, where cells in G2 have approximately twice the amount of DNA compared to cells in 
G1.  As DNA is synthesised in S phase, these cells have a DNA content ranging in between 
that of G1 and G2. Samples were collected over indicated time points and fixed in 4% 
paraformaldehyde (PFA) for 7 minutes at room temperature. Fixed cells were 
permeabilised with 0.2% Triton X-100 for 3 minutes at room temperature before addition 
of 1µg/ml DAPI and analysed by flow cytometry (BD Biosciences LSR Fortessa). Samples 
were recorded using a BD LSR Fortessa flow cytometer and analysed using BD FACS Diva 
software. Cells were gated based on forward scatter area and height, and side scatter area 
and width to remove doublets and select a single cell population only. Cells were excited at 
350nm and recorded with the 450/50nm emission filter. 10,000 events were acquired for 
each sample and the percentage of cells in each cell cycle phase was analysed using FlowJo 
software.  
3.8.2 Annexin V staining for apoptosis  
Annexin V is a 35-36kDa calcium dependent phospholipid-binding protein that has a high 
affinity for phosphatidyl serine (PS). In a normal cell PS is located on the cytoplasmic 
surface of the cell membrane. In apoptotic cells PS is translocated from the inner to the 
outer leaflet of the plasma membrane, exposing PS to the external cellular environment. 
Fluorescently labelled annexin V allows detection of apoptotic cells via binding to PS.  Co-
Chapter 3: Materials and Methods 
91 
 
staining with DAPI, which is impermeable to live cells, enables distinction between dead 
cells and apoptotic cells. Annexin V and DAPI negative are alive, DAPI positive only are 
dead and annexin V positive cells are undergoing apoptosis. 
Cells were treated with VIK targeting siRNA, or transfected with VIK expressing plasmid. At 
indicated time points cells were collected and washed in PBS. 2.5µl of AlexaFluor 647 
annexin V conjugate (Thermo Fischer) was added to each sample in 50µl of 1x annexin 
binding buffer (10mM HEPES, 140mM NaCl, 2.5mM CaCl2, pH 7.4) and incubated for 15 
minutes at room temperature. 200µl of 1mg/ml DAPI diluted in 1x annexin binding buffer 
was added to each sample and cells were analysed by flow cytometry, emission of annexin 
V was recorded at 670/14nm. The unlabeled control, with negative staining for DAPI and 
annexin V, was used to draw gates and differentiate positively stained cells from the 
negatively stained cells. 
 
3.9 Statistical Analysis 
3.9.1 Analysis of in vitro assays 
Data was normalised to control where required and as described. Statistical analysis for all 
cell line assays was performed using GraphPad Prism software. Where there were only two 
treatment groups an un-paired one-way Student’s T-test was performed. A One-way 
ANOVA was performed with a Tukey’s post-hoc test to compare significance between more 
than two treatment groups. Two-way ANOVA with Sidak’s multicomparison test was 
performed when there were treatment groups with two independent variables. All graphs 
show mean of biological triplicates +/- standard deviation unless otherwise stated.  
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3.9.2 Analysis of primary patient data 
SPSS (IBM software) was used to analyse patient samples. A Mann-Whitney test was used 
for two variables and Kruskal-Wallis one-way ANOVA for more than two variables. 
Spearman’s rank correlation was used to determine correlation between two variables and 
is reported as correlation coefficient variable (R). Survival was analysed using a Kaplan-
Meier curve followed by log-rank and cox-regression analysis.  
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4.1 Methylation in breast cancer cell lines 
4.1.1 450K methylation array 
A comprehensive genome wide screen was carried out by the Schmid group to identify 
potential epigenetically silenced genes in breast cancer. Fourteen breast cancer cell lines 
were screened using the 450K-methylation array (Illumina) to identify aberrantly 
methylated regions. The array is designed to analyse regulatory regions covering more 
than 485,000 CpG sites in the human genome. The probes are distributed mainly to cover 
CpG islands but also include the shore regions (up- and down-stream of each CpG island), 
gene bodies and 5’ and 3’ untranslated regions (UTRs). β-values represent methylation 
levels and range from 0 representing the lowest value to 1 representing the highest.  
The methylation array generated a list of candidate genes from which ZNF655 (VIK) was 
selected for further investigation based on the presence of a CpG island within the 5’ 
regulatory regions and high levels of methylation observed. Additionally VIK was chosen 
due to the novelty of the gene in the context of breast cancer and potential functional role 
within the cell cycle, which will be discussed in the following chapters.  
VIK is located on chromosome 7 and has a large CpG island of 1098bp containing 90 CpG 
sites. The CpG island overlaps with the 5’ UTR and is upstream of the coding region (Figure 
4.1A). Methylation was shown to be only slightly variable across the 13 probes located 
within the CpG island. Dense methylation was observed in 6 out of 14 cell lines (Figure 
4.1B), indicating the gene could undergo transcriptional regulation via epigenetic changes. 
 







Figure 4.1 Methylation analysis in breast cancer cell lines. A) Schematic representation of the 
CpG island. The VIK (ZNF655) gene has a CpG island (shown as a green block) within the 5’ 
regulatory region of the gene. Vertical lines below represent methylation array probes targeting 
a single CpG dinucleotide. Red box displays the location of the region analysed for 
pyrosequencing. B) Heat map representation of methylation across a panel of cell lines from a 
450K methylation array. The heat map is colour coded based on β-values (ratio of methylated 
signal to total signal). Out of 14 cell lines, 6 exhibited dense methylation across the CpG island.  
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4.1.2 Pyrosequencing analysis 
To validate the results observed using the 450K array, a pyrosequencing assay was 
designed to investigate the methylation status of the CpG island within the 5’ regulatory 
region of the VIK gene. Based on the methylation array, pyrosequencing primers were 
designed within a more highly methylated region of the island. Genomic DNA was sodium 
bisulphite treated which deaminates unmethylated cytosines to uracils. Subsequent PCR 
amplification leads to incorporation of thymine instead of the original unmethylated 
cytosine. This gives a DNA sequence dependent on the methylation status. Sequencing of 
the DNA allows quantification of methylation by ratio of thymines and cytosines. The 
pyrosequencing assay covered 8 individual CpG sites across the island for all breast cancer 
cell lines. For the normal breast epithelial cell line, MCF10A, pyrosequencing only reliably 
covered 6 CpG sites, with the signal strength tailing off over site 7 and 8, therefore only 6 
sites were evaluated. Methylation of each individual CpG site was determined and an 
average percentage across all CpG sites was used to define methylation status of each cell 
line. 
The non-tumour breast epithelial cell line, MCF10A, was unmethylated, whilst methylation 
varied across the breast cancer cell lines. Pyrosequencing revealed high levels of 
methylation in 8 out of 19 breast cancer cell lines (Figure 4.2A). The same cell lines were 
found to be methylated in both the methylation array and pyrosequencing analysis. Linear 
regression showed close correlation between methylation levels determined by the two 
methods (r2=0.9289, p<0.0001) (Figure 4.2B). Cell lines were mainly either highly 
methylated >60% or had low levels of methylation <11%. Only SKBR3 and MLET5 had a 
more intermediate methylation value of 40% and 39% respectively.  
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Figure 4.2 Pyrosequencing analysis in breast cancer cell lines. A) Methylation was 
analysed by pyrosequencing across a panel of cell lines from breast cancer subtypes and 
normal breast epithelial cells. Each column represents an individual CpG site. Proportion of 
grey boxes represents % methylation at each site. Percentage methylation of each cell line 
was calculated by average methylation across all CpG sites. Mean methylation of biological 
triplicates was calculated to give methylation status for each cell line +/- standard 
deviation. B) Analysis of correlation by linear regression of methylation determined by the 
methylation array and pyrosequencing. y-axis shows β-value from the array probe that 
matched to the region of the CpG island analysed by the pyrosequencing assay. x-axis 
shows % methylation by pyrosequencing.  
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4.2 VIK mRNA expression in breast cancer cell lines 
To ascertain the implication of methylation on VIK expression, mRNA expression of VIK was 
analysed across the panel of breast cancer cell lines.  
VIK is a splice variant of the Zinc Finger 655 (ZNF655) gene. Three different isoforms have 
been characterised and confirmed experimentally. VIK-1, VIK-2 and VIK-3, are produced as 
a result of gene splicing (Figure 4.3) (236). Each isoform has two transcript variants, which 
differ slightly in the 5’UTR, encoding the same protein. VIK-1 is a 57kDa protein containing 
6 zinc finger domains and a separate VAV interacting domain and CDK4 interacting domain. 
The larger 61kDa protein VIK-2 contains these same domains with the addition of a KRAB B 
domain. The smaller 20kDa isoform VIK-3 contains a proline rich domain (Pro), KRAB A 
domain and an unknown domain. There is an additional putative isoform, VIK-4, that has 
not previously been characterised. VIK-4 is a shorter isoform, 12kDa, which does not have 
the known functional domains. The total mRNA expression of all VIK isoforms was 
determined using two separate TaqMan RT-qPCR assays (Figure 4.4A,B). Individual 
expression of each isoform was determined by SYBR Green assays, using primers designed 
to amplify each isoform individually (Figure 4.4C). Primer locations are annotated in Figure 
4.3. All VIK transcripts are covered over the different RT-qPCR assays. Due to the sequence 
similarity of VIK-1 and VIK-2 it was not possible to design separate assays, therefore 
primers were designed to amplify VIK-2 alone and VIK-1 plus VIK-2 combined. Expression of 
VIK-1 alone was determined by subtracting VIK-2 from VIK-1 + VIK-2. All RT-qPCR assays 
showed the same mRNA expression pattern. From this point forward, unless otherwise 
specified, TaqMan assay 1 was used to assess mRNA levels of VIK. 
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Figure 4.3 Diagrammatic representation of the organisation of the VIK (ZNF655) gene and 
alternatively spliced isoforms VIK-1, VIK-2, VIK-3, VIK-4. Each isoform has two transcripts 
encoding the same protein. Location of PCR primers are represented by arrows, over the 
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The cell line panel included the non-tumour breast epithelial line MCF10A and covered a 
range of breast cancer subtypes: HER2 positive, triple negative and ER positive. Cell lines 
exhibited either no detectable mRNA expression of any VIK isoform, or variable expression 
of all three isoforms, with VIK-1 generally being the most highly expressed. There was no 
correlation between VIK expression, or expression of individual isoforms, and breast cancer 
subtype. Within the ER positive group were two cell lines derived from MCF7 that do not 
depend on estrogen for proliferation, the LCC9 and MLET5 cell lines. LCC9 is resistant to 
the ER antagonist fulvestrant (288). MLET5 is resistant to the cytotoxic drug etoposide and, 
whilst still ER positive, is able to grow independently of estrogen (289). There was also no 
difference in VIK expression between the MCF7 cells and the estrogen independent LCC9 
or MLET5, all three had undetectable mRNA levels.  



















Figure 4.4. Analysis of VIK mRNA expression in breast cancer cell lines. A) Total VIK 
isoform mRNA expression determined by TaqMan assay 1. B) Total VIK isoform mRNA 
expression determined by TaqMan assay 2. C) mRNA expression of each separate VIK 
isoform determined by individual SYBR Green assays. mRNA expression was normalised to 
the housekeeping gene RPLPO, average of biological triplicates. There was no correlation 
between VIK expression and breast cancer subtype. Cell lines either expressed variable 
levels of each isoform, or did not express any of the isoforms. 
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4.3 Methylation silences VIK transcription 
The cell lines with no detectable mRNA levels were the same cells to have been 
determined as methylated by pyrosequencing analysis. VIK methylation correlated closely 
with mRNA expression (R=0.842, p<0.0001, Pearson’s correlation coefficient), such that no 
detectable mRNA was observed in cell lines with methylation above 30% (Figure 4.5A). This 
suggests VIK is subject to methylation dependent transcriptional silencing. 
In order to validate whether methylation is a direct mechanism of transcriptional silencing, 
epigenetic mechanisms were inhibited in the methylated cell lines MCF7 and SKBR3 and 
the unmethylated cell line T47D (Figure 4.5B). Cells were treated with 5-aza-2’-
deoxycytidine (AZA) and/or Trichostatin A (TSA). AZA is a cytosine homologue, which binds 
to and inhibits methyl-transferases in proliferating cells leading to global DNA 
demethylation. TSA is a HDAC inhibitor that reduces chromatin condensation. Upregulation 
of VIK mRNA expression was seen following AZA treatment in all methylated lines, 
indicating methylation directly silences VIK transcription. Approximately 100-fold 
upregulation was seen in the MCF7 and 7-fold in the SKBR3. There was a more limited 
increase of 2-fold in the already unmethylated T47D. Treatment with TSA had no effect and 
there was no synergistic effect with combined AZA and TSA treatment. This demonstrates 
the epigenetic regulation of VIK in our cell lines is restricted to DNA methylation. 
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Figure 4.5. Methylation transcriptionally silences VIK. A) Histogram displays mRNA, as 
measured by RT-qPCR total isoform expression assay 1 (left Y-axis). The green line shows % 
methylation, determined by pyrosequencing (right Y-axis). Methylation correlates to no 
detectable mRNA expression. B) Methylation reversal with AZA treatment resulted in 
upregulation of VIK mRNA, treatment with TSA had no effect.  Ct:  untreated control AZA: 
5-aza-2’-deoxycytidine TSA: Trichostatin A. mRNA expression was normalised to the non-
treated control to give a fold change of upregulation. Average of biological triplicates +/- 
standard deviation is shown. 
Chapter 4: Results 
104 
4.4 VIK expression and methylation in primary breast cancer 
samples 
Having established methylation transcriptionally silences VIK expression in breast cancer 
cell lines, we next investigated VIK methylation and expression in primary breast cancer 
samples. An independent breast cancer cohort (Leeds cohort) was analysed as well as 
publicly available data from the Cancer Genome Atlas (TCGA).  The preliminary data in a 
breast cancer patient cohort linked VIK methylation to poor outcome in patients receiving 
tamoxifen treatment. In light of the differential outcome with regards to VIK methylation in 
the preliminary cohort, survival analysis was performed on these two cohorts.  
4.4.1 The Cancer Genome Atlas cohort 
4.4.1.1 Methylation and expression analysis in TCGA cohort 
 
To explore the expression of VIK and the relationship of VIK and VAV1 in primary tissue, in 
silico analysis was carried out using data from TCGA (290). TCGA is a publically accessible 
database with high throughput sequencing and array data plus clinical information from a 
variety of cancer types. Methylation (Illumina Human 450K methylation beadchip), gene 
expression (Illumina HiSeq 2000 RNA sequencing) and matching clinical data was available 
for 587 primary breast cancer tissue samples and 83 normal breast tissue samples. Based 
on the clinical information, tumour samples were divided into breast cancer subtypes: ER+, 
HER2+ ER+, HER2+ ER- and triple negative. Non-tumour samples were tumour-adjacent 
tissue, histologically determined as normal. Expression values are normalised data using 
RNA-seq by expectation maximisation (RSEM) to determine expression levels. Methylation 
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β-values were taken from the methylation array probe that matched to the same region as 
the pyrosequencing primers designed to amplify the region of the CpG island for VIK. 
Normal samples exhibited no methylation across the CpG island, whilst tumour samples 
showed variable methylation across the CpG island (Figure 4.6). Tumour samples exhibited 
significantly higher VIK methylation in comparison to normal tissue. Normal tissue showed 
no methylation for VIK, with a mean methylation β-value of 0.04, ranging from 0.02 to 
0.15. There was approximately a 40% increase in mean methylation β-values in breast 
cancer tissue compared to normal tissue. This was consistent across all breast cancer 
subtypes. Tumour tissues displayed a wide range of methylation β-values, from low levels 
of methylation of 0.02 up to highly methylated 0.83 (Figure 4.7B). All breast cancer 
subtypes had a subset of the population with higher than normal methylation values 
(Figure 4.7C).  
Within the tumour samples VIK methylation inversely correlated to VIK mRNA expression 
(Figure 4.7A). Increase in methylation corresponded to a significant decrease in average 
VIK expression. Tumour samples displayed lower levels of VIK expression in comparison to 
normal samples (Figure 4.7D). This down-regulation was consistent across all breast cancer 
subtypes, with all subtypes exhibiting a proportion of samples with lower than normal VIK 
expression (Figure 4.7E). These results suggest that there is a subset of patients with low 
levels of VIK expression that are subject to transcriptional silencing due to methylation.  
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Figure 4.6. Methylation array analysis 
of TCGA patient cohort. Heat map 
representation of the distribution of 
methylation across the promoter region 
of VIK in 587 patient samples and 83 
normal breast tissue samples. Each row 
represents a single patient. The arrow 
shows the probe that matches to the 
same position as the pyrosequencing 
assay. The heat map is colour coded 
based on methylation -value, ranging 
from 0 (blue) to 1 (red).  
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Figure 4.7 Analysis of VIK expression and methylation in primary breast cancer samples 
from TCGA dataset. A) VIK methylation significantly correlated to VIK expression. Increased 
methylation corresponded to decreased VIK expression. Methylation is shown as 
methylation β-value as determined by 450K methylation array, and expression was 
determined by RNAseq. (P<0.0001 Spearman’s correlation test). B) Distribution of 
methylation in normal and tumour samples. Error bars represent the mean +/- standard 
deviation. C) Distribution of methylation across breast cancer subtypes compared to normal. 
D) VIK expression in normal and tumour samples. E) Distribution of VIK expression across 
each breast cancer subtype compared to normal tissue. *P<0.05, **P<0.01 ***P<0.001 
Mann-Whitney test between tumour and normal samples. Kruskal-Wallis test between 
normal and breast cancer subtypes. 
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VIK was initially characterised due to its interaction with VAV1 and there is potentially a 
compensatory mechanism between these two proteins (277). Therefore, VAV1 expression 
was also evaluated in the breast cancer cohort, to determine if there was a correlation 
between VIK and VAV1 expression. Conversely to VIK expression, average VAV1 expression 
was significantly upregulated in tumour samples compared to normal tissue (Figure 4.8A), 
and this was seen across all subtypes (Figure 4.8B). However, there was no correlation 
between VIK and VAV1 expression (Figure 4.8C). Additionally, when tumour samples were 
separated into VIK high or low expressing, determined as the mean expression of normal 
samples plus or minus 2 standard deviations, there was no difference in VAV1 expression 
(Figure 4.8D). This indicated no clear relationship between VIK and VAV1 expression in the 
breast cancer tumour samples.  
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Figure 4.8 Analysis of VAV1 expression in primary breast cancer samples from TCGA 
dataset. A) Distribution of VAV1 expression in tumour samples compared to normal 
samples. VAV1 expression was significantly higher in the tumour population compared to 
normal samples. ***P<0.0001 Mann-Whitney test. B) VAV1 expression was higher in all 
breast cancer subtypes compared to non-tumour samples. Mean expression was 
significantly higher in all subtypes compared to normal tissue. Kruskall-Wallis test *P<0.05 
**P<0.001 C) There was no correlation between VIK and VAV1 expression in the tumour 
samples, assessed by Spearman’s test. D) Tumour samples were divided into VIK high-
expressing and VIK low-expressing. No difference was seen in VAV1 expression between 
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4.4.1.2 Survival analysis in TCGA cohort 
 
Having demonstrated differential expression and methylation in tumour tissue compared 
to non-tumour tissue, we investigated the implication of this methylation on patient 
outcome within this cohort. 
Tumour tissues were divided into methylated and unmethylated, based on the single 
methylation probe that matched to the same region as the pyrosequencing assay. The 
normal breast samples displayed baseline levels of methylation for VIK. Therefore, mean 
methylation of the normal tissue plus three standard deviations was used as a cut-off to 
determine VIK methylated samples. This gave a cut-off β-value of 0.135. Using this cut-off, 
9.9% of the tumour population was methylated for VIK. There was no significant difference 
in the median overall survival time between the methylated and unmethylated groups. 
Multivariate cox-regression analysis showed that of the characteristics tested only age and 
tumour subtype significantly correlated to patient overall survival (Figure 4.9A). Neither VIK 
methylation (p=0.954) or VIK expression (p=0.530) had a significant effect on survival. 
Kaplan-Meier curve and log-rank test showed no significant difference in survival time 
between methylated and unmethylated patients (Figure 4.9B). 
 
















Figure 4.9. Methylation of VIK and patient outcome in TCGA dataset, using a cut-off 
based on a single probe A) Clinical characteristics of VIK methylated and unmethylated 
breast cancer patient samples. Patients were divided into methylated and unmethylated 
based on the methylation probe corresponding to the pyrosequencing assay, giving a cut 
off β-value of 0.135, with 9.9% of the population characterised as methylated. Columns 
show number of patients unmethylated or methylated for each characteristic. P-values 
refer to differences between the methylated and unmethylated groups and survival 
analysis by multivariate cox-regression. B) Kaplan Meier curve for overall survival with 
respect to VIK methylation status. The log-rank test was used to analyse significant effect 
on patient outcome. 
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However, this analysis only took into account one region of the CpG island. The 
methylation array showed some variable methylation across the different probes within 
the CpG island, with some probes exhibiting higher methylation than in other regions 
(Figure 4.6). Therefore survival analysis was also carried out taking into account average 
methylation of the whole CpG Island. Average methylation across all CpG island probes for 
the normal tissue, plus 3 standard deviations was used as a cut-off for methylation. This 
gave a cut-off methylation β-value of 0.167, above which samples were considered to be 
methylated. This corresponded to 14% of patients being methylated for VIK. A slightly 
higher methylated population than described above when only accounting for the single 
methylation probe. Survival analysis based on this methylated population showed a 
potential trend towards a poorer outcome in patients methylated for VIK, with the log-rank 
test approaching significance (p-value 0.074) (Figure 4.10). However, multivariate cox-
regression analysis also taking into consideration age, tumour grade and tumour subtype 
showed VIK methylation had no significant effect on patient outcome (Figure 4.10).  
It should be noted that there were few survival events over the entire cohort, only 66 out 
of a total of 587 patients. This, in combination with the relatively small proportion of 
patients within the methylated group, makes interpretation of survival data from this 
cohort inconclusive.  
 
 


















Figure 4.10 Methylation of VIK and patient outcome in TCGA dataset, using a cut-off 
based on the entire CpG island. A) Clinical characteristics of VIK methylated and 
unmethylated breast cancer patient samples. Patients were divided into methylated and 
unmethylated, based on average methylation across the whole CpG island. This gave a cut-
off β-value of 0.167, above which samples were considered methylated, corresponding to 
14% of the population. Columns show number of patients unmethylated or methylated for 
each characteristic. P-values refer to differences between the methylated and 
unmethylated and survival analysis by multivariate cox-regression. B) Kaplan Meier curve 
for overall survival with respect to VIK methylation status.  
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4.4.2 Leeds Breast Cancer Cohort 
4.4.2.1 Methylation analysis in Leeds breast cancer cohort 
 
A second cohort of 187 formalin-fixed paraffin embedded (FFPE) primary breast cancer 
tissue samples was analysed for methylation of VIK. Methylation was examined using the 
same pyrosequencing assay as described for the breast cancer cell lines, giving a % 
methylation value for 6 individual CpG sites for each patient sample. In this population 
there was a small distribution of methylation values across the cohort. Although there was 
one patient was much more highly methylated than the rest of the population, with an 
average 42% methylation (Figure 4.11A).  
There were no normal tissue samples to determine a cut-off for methylated samples, so 
average methylation of all 6 CpG sites across the population was taken to assess baseline 
levels of methylation. This determined a cut-off value of 10.6%. There were two CpG sites 
(CpG site 2 and site 5) that displayed the most variation in methylation. Therefore an 
average of these two sites was taken plus 2 standard deviations, and all samples with 
average methylation above 10.6% were determined to be methylated (Figure 4.11B). This 
corresponded to 13 patients and thus 7% of the population being classified as methylated.  
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Figure 4.11 Methylation analysis in the Leeds primary breast cancer patient cohort. 
Methylation was assessed by pyrosequencing. A) Distribution of methylation across the 
tumour population. B) Heat map representation of methylation across the 6 CpG sites. 
Based on average methylation plus 2 standard deviations, a cut off of 10.6% was set. All 
values above this were determined as methylated, corresponding to 7% of the population.  
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4.4.2.2 Survival analysis in Leeds breast cancer cohort 
 
As described the tumour samples were separated into methylated and unmethylated 
populations and methylation status analysed for potential as an indicator of overall patient 
survival. Multivariate cox-regression analysis revealed only age and tumour grade to 
significantly correlate to survival outcome. Methylation was not found to impact upon 
patient outcome (Figure 4.12). However, the methylated population size was small and a 
larger series of patients would be required to properly evaluate the effect of VIK 
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Figure 4.12. Methylation of VIK and patient outcome in the Leeds breast cancer cohort. 
A) Clinical characteristics of VIK methylated and unmethylated breast cancer patient 
samples. Patients were divided into methylated and unmethylated. Columns show number 
of patients unmethylated or methylated for each characteristic. P-values for each 
characteristic refer to differences between the methylated and unmethylated groups and 
survival analysis by multivariate cox-regression. B) Kaplan Meier curve for overall survival 
with respect to VIK methylation status and survival analysed by the log-rank test. 
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4.5 VIK protein expression in breast cancer cell lines 
So far we have established VIK is subject to methylation dependent transcriptional 
silencing in both breast cancer cell lines and primary breast cancer samples. To further 
characterise VIK expression in breast cancer, we analysed protein expression in breast 
cancer cell lines. 
4.5.1 Western blot analysis 
Firstly, VIK protein expression was assessed by western blot across the panel of breast 
cancer cell lines.  Detection by western blot with commercial antibodies proved difficult, 
multiple antibodies were tested, and two commercial antibodies were optimised for 
western blot analysis, detecting a band at approximately 60kDa. Both antibodies detected 
a single band but at slightly different sizes. Potentially these antibodies are detecting VIK-1 
at 57kDa and VIK-2 at 61kDa. However, protein expression did not correlate to mRNA 
expression. Methylated cell lines, with no detectable mRNA, still gave a protein band with 
both antibodies (Figure 4.13B). In order to confirm the accuracy of commercial antibodies 
for detecting VIK, a custom antibody against VIK was generated (Eurogentech). An epitope 
was selected to be different from either commercial antibody, within an immunogenic 
region of the protein and to be within a region that was not highly conserved with other 
proteins. The custom antibody detected a higher band than anticipated, at approximately 
80kDa, which does not correspond to any known isoforms of VIK (Figure 4.13B). Potentially 
this antibody is detecting a different splice variant of VIK that has not been previously 
characterised or it is detecting a large post-translational modification to VIK. Again, protein 
expression using the custom antibody did not correlate to mRNA expression, and all 
methylated cell lines displayed protein bands. In fact, all three antibodies showed different 
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expression levels across the cell line panel, and none of the protein levels correlated to any 
of the mRNA assays.  
As methylation status did not correlate to protein expression, we examined if methylation 
reversal would upregulate protein levels. The methylated MCF7 and SKBR3, and 
unmethylated T47D cell lines were treated with AZA and/or TSA. Whilst methylation 
reversal significantly upregulated mRNA expression as shown above (Figure 4.5B), it did not 
however alter protein expression. Protein levels remained the same following treatment 
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Figure 4.13. VIK protein detection in breast cancer cell lines. A) Diagram of known VIK 
protein isoforms, and epitopes of each antibody. There are 3 confirmed proteins VIK-1 
(57kDa), VIK-2 (61kDa) and VIK-3 (20kDa). B) Representative western blot images, showing 
protein expression across a panel of breast cancer cell lines using 3 different antibodies 
against VIK and the corresponding β-actin control. Methylated cell lines are labelled in red, 
whilst unmethylated cell lines are labelled in black.  
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Figure 4.14. Methylation reversal does not upregulate protein. Methylated cell lines, 
MCF7, SKBR3 and the unmethylated T47D, were treated with a demethylating agent (AZA), 
a histone deactylatalase inhibitor (TSA), or both. Western blot analysis of protein 
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So far we have been unable to correlate baseline mRNA expression to protein levels, or 
upregulation of mRNA to protein, leading us to question the accuracy of the detected 
protein. To further validate if the antibodies are correct, levels of VIK were modulated in 
cell lines and western blot performed to determine if the protein was also modulated. The 
unmethylated, VIK expressing cell lines T47D, SUM44 and MCF10A were transfected with 
VIK siRNA targeting all isoforms. siRNA treatment resulted in depletion of the protein via 
western blot with all antibodies (Figure 4.15). This would suggest that the antibodies are all 
correctly detecting VIK.  
However, this did not answer the question regarding protein expression in methylated cell 
lines, therefore we attempted to modulate protein levels in methylated cell lines also 
(Figure 4.16). siRNA treatment in the methylated MCF7 cells, with no detectable VIK 
mRNA, did not result in loss of the protein. Upon overexpression of VIK-1 in the MCF7, 
using a pcDNA3.1 VIK-1 expression plasmid, there was no increase in protein level with any 
antibody.  
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Figure 4.15 Protein detection of VIK following siRNA knockdown in unmethylated cell 
lines. Protein expression was detected by western blot using the commercial and custom 
antibodies after modulating VIK levels by siRNA knockdown. A representative western blot 
is shown alongside quantification of protein levels by densitometry, normalised to the β-
actin loading control and shown relative to the non-targeting siRNA control. A) Using the 
commercial antibodies to detect protein, VIK targeting siRNA knocked-down protein in the 
unmethylated T47D and B) SUM44 cells. C) The custom antibody also showed decreased 
protein following siRNA treatment in T47D cells and D) MCF10A cells.  
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Figure 4.16. Protein expression in methylated MCF7 cells following modulation of VIK 
expression. A) VIK targeting siRNA did not alter protein expression with either commercial 
antibody 1 or B) the custom antibody. C) VIK-1 over expression with a pcDNA3.1 expression 
vector in methylated cell line, MCF7, did not increase the protein band when compared to 
transfection with pcDNA3.1 vector only (VO). D) The custom antibody also did not show 
increased protein following transfection with a pcDNA3.1 VIK-1 expressing plasmid. A 
representative western blot is shown, alongside protein quantification. Protein was 
quantified relative to -actin and normalised to the control.  













Figure 4.17. Immunopreciptation (IP) of EGFP-tagged VIK. HEK293T cells were 
transfected with a pEGFP-VIK vector or pEGFP vector only (VO). A) RT-qPCR confirming 
upregulation of VIK mRNA following transfection. Representative western blot of pEGFP-
VIK transfected cells probed with B) GFP antibody C) custom VIK antibody D) commercial 
VIK antibody. GFP antibody clearly detects the overexpressed EGFP-tagged VIK protein. 
Immunoprecipitation was performed on transfected cells, using a GFP antibody to pull 
out the EGFP tagged VIK protein. IP samples were run on a western blot and probed for 
E) GFP F) custom VIK antibody G) commercial VIK antibody. Both VIK antibodies and the 
GFP antibody detect the same strong band in cells transfected with pEGFP-VIK.   
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Thus far, protein expression did not correlate to baseline mRNA levels and increased mRNA 
expression did not translate to increased protein. This led to concerns for the accuracy of 
our antibodies. To confirm if the antibodies were actually detecting VIK, 
immunoprecipitation (IP) was performed followed by mass spectrometry analysis of the 
protein band. Ideally endogenous IP of VIK from a methylated and unmethylated cell line 
would have been carried out, to compare the protein in each. However, neither the custom 
nor commercial antibody was found suitable for immunoprecipitation. Therefore, full 
length VIK-1 was cloned into a pEGFP vector, and transfected into HEK293T. RT-qPCR 
confirmed over expression of VIK in cells transfected with pEGFP-VIK compared to pEGFP 
vector only (Figure 4.4A).  The GFP antibody detected a strong band in the pEGFP-VIK 
transfected cells, that was not present in the vector only transfected cells (Figure 4.17B), 
although this band was not clearly detected by the commercial or custom antibody (Figure 
4.17 C,D). Following IP, the GFP antibody and both VIK antibodies detected the same single 
band at the same size, approximately 100kDa, in pEGFP-VIK transfected cells. This indicates 
both the custom and commercial antibody do detect VIK (Figure 4.17 E-G). The IP product 
was resolved on an acrylamide gel to separate out the proteins and the gel was stained 
with coomassie blue. The gel was cut around the band corresponding to pEGFP-VIK and 













Figure 4.18. Top results from mass spectrometry. Following IP for EGFP-VIK, the IP sample 
was separated on an acrylamide gel, stained with coomassie blue and the band 
corresponding to EGFP-VIK analysed by mass spectrometry. ZNF655 (VIK) was among the 
top protein scores. Protein score is the parameter characterising the reliability of protein 
identification. 
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Mass spectrometry produced a list of proteins with a corresponding protein score. This is 
the measure characterising the reliability of protein identification. Out of 419 proteins in 
total, 75 proteins had a high score above 100. Of the top scoring proteins, VIK (ZNF655) 
was 4th highest with a score of 694.33 (Figure 4.18). The presence of VIK indicates the 
antibodies could be correctly detecting VIK. However, it is possible that our antibodies 
detect another protein from the list. Although, comparison of the antibody epitopes and 
the protein sequences demonstrated no region for the antibodies to bind to any of the 
proteins from the list other than VIK. Therefore it is likely the other proteins are unspecific. 
Many of the proteins listed were heat shock proteins, which function as chaperone 
proteins. Additionally, a number of the highly scoring proteins are all involved in the DNA 
damage response (PARP, XRCC5, SSRP1, DDX21, NUCL).   
4.5.2 Immunofluorescence  
To further understand the protein expression of VIK, it may be important to consider 
localisation of the protein, and therefore, immunofluorescence was performed to confirm 
where the protein we detected was localised. The only paper regarding VIK has shown 
immunofluorescence of VIK with primarily nuclear staining (277). Neither commercial 
antibody was found to be suitable for immunofluorescence, however the custom antibody 
was optimised. The methylated MCF7 and unmethylated T47D were stained using the anti-
VIK antibody and DAPI for nuclear staining (Figure 4.19). In the methylated and 
unmethylated cell lines, VIK was observed in both the nucleus and the cytoplasm. 
However, contradictory to expectation, VIK was predominantly in the cytoplasm, in both 
the methylated and unmethylated cell lines.  
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Figure 4.19. Immunofluorescence reveals sub-cellular localisation of VIK. Cells were 
stained for VIK (green) and nuclear staining with DAPI (blue). VIK was observed in both the 
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4.6 Inducible expression of VIK  
As we were unable to show how VIK protein expression correlated with mRNA levels or 
methylation status, it is possible that whilst methylation does not affect baseline levels of 
VIK protein, methylation might inhibit inducible expression of the protein. To investigate 
this, the methylated cell line MCF7 and unmethylated cell line, T47D, were treated with 
conditions that might induce VIK expression.  
4.6.1 Growth factor stimulation 
We hypothesised that methylation of VIK might inhibit inducible expression of VIK, by 
inhibiting binding of transcription factors in the gene promoter region. To identify any 
putative transcription factor binding domains, an in silico analysis of the 5’UTR region, 
which is overlapped by the CpG island, was performed using MatInspector software (291). 
This analysis compared the input DNA sequence with known nucleotide binding motifs of 
transcription factors or co-activators. An algorithm assigns each putative binding site 
match with a score between 0 and 1, which indicates the similarity between the input DNA 
sequence and the database of known binding motifs. A score of 1 reflects a perfect match 
of the sequence to the identified binding motif. Any score above 0.8 indicates the 
transcription factor could bind to the DNA sequence, although there may be some 
nucleotide deviations between the known database sequence and the input DNA 
sequence. This analysis produced a list of 315 matches, of which 242 had ‘good’ scores 
above 0.8 and 150 scored above 0.9. There were 8 matches with a perfect score of 1.0. 
These included FOXP1 (Forkhead box protein P1), TAIP3 (TGF- induced apoptosis protein 
3) and signal transducer and activator of transcription 1 (STAT1). These are all activated by 
growth factor stimulation. FOXP1 and TAIP3 by transforming growth factor  (TGF-) and 
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STAT1 by epidermal growth factor (EGF), therefore we needed to confirm if either of these 
growth factors would induce VIK expression.  
EGF treatment did not alter VIK mRNA expression in MCF7 cells, but did show a potential 
upregulation of mRNA in T47D cells following 8 hours EGF treatment (Figure 4.20A), 
however there was no change in protein levels in either cell line (Figure 4.20B). In both cell 
lines, treatment with TGF- had no effect on mRNA (Figure 4.20C) or protein via western 
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Figure 4.20. TGF-β or EGF treatment does not induce VIK expression. Methylated MCF7 
and unmethylated T47D were treated with either 40ng/ml EGF or 10ng/ml TGF- or a 
vehicle control, for 8 hours. A) RT-qPCR analysis after EGF treatment. There was no change 
in MCF7 cells, but some upregulation in T47D cells. B) Quantification of protein levels 
showed no change in either cell line upon EGF treatment. Underneath is a representative 
western blot, samples are in the same order as the histogram above. C) RT-qPCR analysis 
revealed there was no change in mRNA levels following TGF- treatment. D) Quantification 
of protein expression following TGF- treatment showed no change in protein levels, 
alongside a representative western blot image. Graphs show average of duplicate 
experiments +/- SD. 
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4.6.2 Hypoxic stress response 
To determine if VIK expression might be induced with the context of a generalised stress 
response, cells were placed under hypoxic stress via incubation at 1% oxygen (Figure 4.21). 
Hypoxic conditions had no effect on mRNA levels in the methylated MCF7 cells, mRNA 
expression remained undetectable. However, following protein detection with the custom 
antibody, the MCF7 did show a nearly 2-fold increase in protein levels at 24 hours, but less 
so at 48 hours. In the unmethylated T47D, 24 hours in hypoxia induced a modest mRNA 
induction, and significantly higher mRNA was observed at 48 hours. The T47D 
demonstrated a significantly larger increase in protein expression, than the MCF7, with a 5-
fold increase in protein at 24 hours and 3-fold higher at 48 hours. 
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Figure 4.21 Hypoxic conditions induce VIK expression. The methylated MCF7 cell line and 
unmethylated T47D were cultured in 1% oxygen (Hypoxia) or normal 20% oxygen (Ct). A) 
RT-qPCR analysis shows small induction of mRNA at 24 and further induction at 48 hours in 
T47D cells in hypoxic conditions. mRNA levels in MCF7 cells remained undetectable. B) 
Quantification of western blot analysis of VIK protein levels. Protein levels were normalised 
to β-actin loading control. C) Representative western blot image. Samples are in the order 
of the histogram above. Graphs display mean of triplicates +/- standard deviation. 
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4.7 Summary 
Across a panel of breast cancer cell lines VIK expression was variable. The normal cell line 
MCF10A, was VIK expressing and unmethylated. Methylation closely correlated to VIK 
mRNA expression, with VIK mRNA undetectable in all methylated cell lines. Additionally, 
reversal of methylation upregulated mRNA expression. Together, this demonstrates a 
mechanism for methylation dependent transcriptional silencing of VIK, although we were 
unable to correlate protein expression with methylation or mRNA.  
Analysis of methylation in patient cohorts indicated approximately 7-14% of breast cancer 
patients to be methylated for VIK. Compared to normal samples, primary tumour samples 
exhibited higher levels of VIK methylation and decreased expression of VIK. Methylation 
significantly correlated to VIK expression, indicating DNA methylation transcriptionally 
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5.1 Modulating levels of VIK induces cell death 
Having established that promoter methylation results in transcriptional silencing of VIK 
mRNA, investigation began into the functional consequences of this silencing in breast 
cancer. Firstly, we began by overexpression of VIK in methylated cell lines and knocking 
down VIK isoforms in unmethylated cell lines.  
5.1.1 Overexpression of VIK induces cell death 
To investigate the effect of ectopic VIK expression in methylated cell lines, cells were 
transfected with either a pcDNA3.1 vector only (VO) or full length VIK-1 expression vector, 
followed by antibiotic selection over 7 days for successfully transfected cells. However, 
ectopic expression of VIK-1 resulted in cell death. Whilst vector only cells grew normally 
after stable transfection and selection, cells over-expressing VIK-1 were unable to survive 
(Figure 5.1). This was true for both methylated cell lines (MCF7, BT474) and also the 
unmethylated cell line T47D, demonstrating cells will not tolerate overexpression of VIK-1 
regardless of endogenous expression levels.  
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Figure 5.1 Over-expression of VIK-1 causes cell death. A) Cells were transfected with an 
empty pcDNA3.1 vector (VO) or pcDNA3.1 vector containing full length VIK-1. After 
selection with G418 treatment for 7 days, number of live cell was determined by MTT 
assay. B) Representative image following transfection with vector only (VO) or pcDNA3.1-
VIK for 7 days in T47D cells. C) RT-qPCR confirms upregulation of VIK mRNA following 3 
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5.1.2 Knockdown of VIK induces cell death via apoptosis 
To determine the functional role of loss of VIK expression, VIK was knocked down in 
unmethylated, VIK mRNA expressing cell lines. As there are multiple transcripts and 
isoforms of VIK, the siRNA was required to knockdown all isoforms. Of all siRNA’s tested, 
only three were able to reduce the mRNA levels of VIK. When tested across all RT-qPCR 
assays only siRNA 2 and siRNA 3 showed mRNA knockdown of all isoforms (Figure 5.2A). 
siRNA 2 gave at least 80% knockdown across all assays compared to the non-targeting 
siRNA control. Analysis of surviving cells following knockdown by MTT assay displayed 
significant cell death after treatment with both siRNA 2 and siRNA 3. However, siRNA 3 
displayed significantly more cell death than siRNA 2 leaving only 16% of cells alive at day 5 
(Figure 5.2B). Therefore, all following knockdown experiments were conducted using siRNA 
2, so there would be sufficient cells alive for analysis. 
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Figure 5.2 Optimisation of VIK siRNA knockdown in T47D cells.  A) VIK mRNA expression 
following 72 hours treatment with VIK siRNA. Three VIK targeting siRNAs were tested 
across all RT-qPCR assays. mRNA was analysed relative to the housekeeping gene RPLPO 
and each siRNA normalised to the non-targeting siRNA control. B) Proportion of cells 
surviving after day 5 of VIK knockdown relative to the non-targeting siRNA. Surviving cells 
were assessed by MTT assay. ****P<0.0001 1-way ANOVA. 
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As there was significant cell death at 5 days post transfection, the proportion of surviving 
cells was followed over time after siRNA treatment in unmethylated cell lines. Reduction of 
VIK mRNA resulted in gradual cell death, as measured by MTT assay, over time (Figure 5.3). 
Cells were treated with siRNA for up to 7 days, mRNA analysis showed successful 
knockdown of VIK compared to the non-targeting control siRNA. In the T47D, 20% of cells 
died after 3 days of knockdown increasing by day 5 to 60%. The SUM44 showed 10% cell 
death at day 3 increasing to 40% at day 4. Additionally siRNA knockdown caused cell death 
in the normal breast cell line MCF10A. The normal breast cell line was in fact more 
sensitive to VIK knockdown. Only half of the cells survived after 2 days of siRNA treatment, 
dropping to 10% on day 4, and the cells began to recover as the VIK mRNA expression 
increased again on day 7. These results indicate that the death inducing effects of VIK 
modulation is not tumour specific. 
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Figure 5.3 VIK knockdown is lethal to breast cancer cells. Cancer cell lines A) T47D B) 
SUM44 and the normal breast cell line C) MCF10A were transfected with VIK targeting 
siRNA or a non-targeting control. Over time, the proportion of surviving cells was measured 
by MTT assay. The histogram displays VIK mRNA levels normalised to the non-targeting 
control (left Y-axis). The red line shows % of surviving cells with VIK knockdown normalised 
to the non-targeting control (right Y-axis).  
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Having established cells do not survive with reduced levels of VIK expression, we sought to 
determine the mechanism by which cells were dying. Therefore apoptosis was 
investigated. Apoptosis is a tightly controlled process of cell death, co-ordinated by a 
complex event of signalling cascades involving caspase activation, cleavage of intracellular 
proteins, exocytosis of cellular contents leading to eventual shrinkage of cells and 
phagocytosis. A key event in the earlier stages of apoptosis is translocation of 
phosphatidylserine (PS) to the extracellular membrane, aiding phagocytosis (292). 
Externalisation of PS can be measured using annexin V. Another marker of cell death is 
uptake of DAPI, which is excluded by live cells. This allows distinction between alive, dead, 
and apoptotic cells. Annexin V and DAPI negative are alive, DAPI positive only are dead and 
annexin V positive cells are undergoing apoptosis. All cell lines showed some apoptosis and 
cell death following transfection with the non-targeting siRNA alone, especially the 
MCF10A and SUM44 cells which were particularly sensitive to siRNA transfection. In T47D 
cells there was a significant increase in annexin V staining, with VIK knockdown doubling 
the proportion of apoptotic cells (Figure 5.4A). SUM44 cells also showed a trend for 
increased annexin V staining with an increase from 17% apoptotic cells with control siRNA 
to 29% with VIK knockdown (Figure 5.4B). In concordance with the MTT cell survival 
analysis, the non-tumour cell line, MCF10A, showed a higher proportion of cells in 
apoptosis. Knockdown of VIK significantly increased annexin V staining, with 76% of cells in 
apoptosis (Figure 5.4C). 
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Figure 5.4 Knockdown of VIK induced apoptosis. The VIK expressing tumour cell lines A) 
T47D and B) SUM44 or the normal cell line C) MCF10A were transfected with siRNA 
targeting VIK or a scrambled non-targeting control. After 5 days knockdown cells were 
stained for DAPI or annexin V. Cells negative for DAPI and annexin V were considered alive, 
cells positive for DAPI but negative for annexin V cells were dead, whilst cells positive for 
annexin V were undergoing apoptosis. Proportion of cells in each state is shown in the 
histogram, alongside an example flow cytometry plot. *P<0.05 ***P<0.001 2-way ANOVA.  
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To confirm apoptosis with a second marker, cleavage of poly(ADP-ribose) polymerase 
(PARP) was assessed. Full length-PARP is an 116kDa protein involved in DNA repair. During 
apoptosis the protein is cleaved into an 89kDa fragment by activated caspases (293).  Both 
the tumour cell lines, T47D and SUM44, and the non-tumour line MCF10A, showed 
significantly increased levels of cleaved PARP after VIK knockdown when compared to the 
non-targeting siRNA (Figure 5.5). The increased cleavage of PARP, in combination with 
increased annexin V staining, shows VIK knockdown induces apoptosis.  
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Figure 5.5. VIK knockdown increased cleavage of PARP. Western blot analysis of PARP and 
cleaved PARP in A) T47D B) SUM44 and C) MCF10A cells. An example western blot and 
quantification of triplicate blots is shown. Western blots were quantified by densitometry, 
relative to the -actin loading control and normalised to the non-targeting control siRNA.  
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5.2 The effect of VIK on sensitivity to endocrine treatment.   
The preliminary patient cohort linked VIK methylation to poor outcome in patients 
following treatment with tamoxifen. Additionally VIK was associated with lower ER 
expression and an increased risk of recurrence in tamoxifen-treated patients. This 
suggested a role for VIK in endocrine resistance; therefore we wanted to investigate the 
effect of VIK on sensitivity to endocrine therapy in vitro. 
5.2.1 VIK expression is not induced by estrogen 
To determine if VIK might have a role in ER+ breast cancer via an involvement with 
estrogen signalling, we hypothesised that VIK expression might be induced by estrogen. 
Therefore, MCF7 (VIK methylated) and T47D (VIK unmethylated) were treated with 
estradiol (E2) for 1 hour and 8 hours.  
No significant increase in VIK mRNA was seen following estradiol treatment in either the 
methylated or unmethylated cell line. Induction of MYC, a well-characterised downstream 
target of estradiol, confirmed cell response to estradiol treatment. In MCF7, estradiol 
induced greater than 2-fold increase in MYC mRNA at 1 hour, sustained until 8 hours. T47D 
cells exhibited an initial 4-fold upregulation following 1 hour, and 1.7-fold increase at 8 
hours. However, no significant increase in VIK mRNA was seen following estradiol 
treatment in either the MCF7 or T47D cell line. VIK mRNA remained undetectable in the 
methylated MCF7 cell line, and there was no change in expression levels in the 
unmethylated T47D. 
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Figure 5.6. VIK expression is not induced by estradiol. A) The VIK methylated cell line 
MCF7 and unmethylated cell line T47D were stimulated with estradiol for 1 hour and 8 
hours. There was no change in mRNA following treatment. mRNA expression is normalised 
to the RPLPO housekeeping gene. B) Expression levels of MYC mRNA following estradiol 
treatment, estradiol induces upregulation of MYC expression. mRNA levels are normalised 
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5.2.2 VIK expression is not a determinant of sensitivity to tamoxifen 
To investigate any role of VIK in sensitivity to endocrine therapy in vitro, VIK was knocked 
down in the ER+ VIK expressing cell lines, T47D and SUM44. Following siRNA knockdown, 
IC50 (the drug concentration required to kill 50% of cells) determination was performed to 
evaluate sensitivity to tamoxifen. Given that VIK methylation was associated with 
increased risk of recurrence in patients following tamoxifen treatment, it might be 
expected that knockdown of VIK would increase resistance to tamoxifen in sensitive cell 
lines. However, VIK knockdown did not affect sensitivity to tamoxifen. No difference was 
seen in IC50 values after transfection with the VIK targeting siRNA when compared to a non-
targeting siRNA control in either T47D or SUM44 cells (Figure 5.7).  
As previously mentioned there was no correlation between VIK expression and expression 
of ER in breast cancer lines (Figure 4.4). Additionally, there was no change in VIK expression 
levels between the MCF7 cells and the LCC9, the endocrine resistant cell line, or MLET5, 
the estrogen independent cell line, both derived from the MCF7. All three cell lines were 
methylated and showed no detectable VIK mRNA levels. These results suggest that VIK is 
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Figure 5.7 VIK and tamoxifen sensitivity. Following transfection with either a non-
targeting control siRNA or VIK-targeting siRNA, cells were treated with a range of 
tamoxifen doses for three days to determine IC50 value. A) Representative survival curve 
for T47D cells and B) average IC50 values.  C) Representative survival curve for SUM44 cells 
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5.3 VAV1 compensates for loss of VIK 
VIK-1 was first identified via its interaction with VAV1, where VIK-1 and VAV1 were 
suggested to have a coordinated role within cell cycle regulation (277). To investigate this 
relationship further, VAV1 expression across the breast cancer cell line panel was 
determined by RT-qPCR (Figure 5.8A). The non-tumour MCF10A breast cell line did not 
express VAV1 mRNA. There was variable expression of VAV1 across the panel of breast 
cancer lines, with no correlation to any particular subtype. VAV1 expression levels did not 
correspond to VIK methylation status. 
Following VIK siRNA knockdown in the unmethylated cell lines, an increase in VAV1 mRNA 
was observed (Figure 5.8B). In the T47D cells, which express VAV1 endogenously, almost 2-
fold increase of VAV1 was observed after 3 days VIK siRNA treatment, this was sustained 
until day 7. In the SUM44, a cell line that ordinarily expresses very low levels of VAV1, a 2-
fold increase was seen also at day 3, after which VAV1 levels returned to normal (Figure 
5.8C). Additionally, VAV1 knockdown in T47D cells resulted in an increase in VIK mRNA at 
48 hours, and then VIK mRNA was again downregulated to nearly normal levels (Figure 
5.8D). However, VAV1 knockdown did not affect VIK expression in the methylated cell line, 
MCF7. mRNA levels of VIK remained undetectable following siRNA knockdown of VAV1 
(Figure 5.8E). These results support a compensatory mechanism between VIK and VAV1 
expression.  
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Figure 5.8. A) VAV1 mRNA expression across a panel of breast cancer cell lines, determined 
by RT-qPCR. The cell lines are divided into VIK methylated and VIK unmethylated. VAV1 
expression did not correspond to VIK methylation. B) VAV1 mRNA levels (orange bars) 
following VIK siRNA knockdown (blue bars) over time in T47D cells and C) SUM44 cells. D) 
VIK mRNA levels (blue bars) after VAV1 siRNA knockdown (orange bars) in the 
unmethylated T47D cells and E) methylated MCF7 cells. Graphs show mRNA normalized to 
the non-targeting siRNA control at each indicated time point. 
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5.4 Summary 
Methylated and unmethylated breast cancer cell lines were unable to survive over-
expression of VIK. Additionally, knockdown of VIK caused cell death via apoptosis, as 
demonstrated by increased extracellular PS and cleavage of PARP. This effect was not 
cancer-specific, but also occurred in normal breast cells. This suggests an optimum VIK 
expression level that is important for cell survival.  
Although a preliminary patient cohort indicated a role for VIK in endocrine resistance, in 
vitro analysis suggests VIK expression does not affect sensitivity to tamoxifen. In 
unmethylated cell lines VAV1 was upregulated in response to VIK knockdown, and VIK was 
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The previous publication regarding VIK function gave evidence for a role of VIK in cell cycle 
progression. Houlard et al (277) demonstrated VIK overexpression to inhibit the 
progression through the G1/S checkpoint in the leukaemia cell line K562, potentially due to 
an interaction with CDK4. There is no published data on the role of VIK within the cell cycle 
in breast cancer, thus we wanted to determine how VIK might modulate cell cycle 
progression in breast cancer. It was of particular interest that VIK has been shown to 
interact with CDK4. Selective CDK4/6 inhibitors are promising to be an effective novel 
therapy in ER positive breast cancer. Therefore we sought to determine if VIK expression 
has an effect on sensitivity to CDK4/6 inhibition. 
6.1 VIK-1 and the cell cycle 
6.1.1 VIK knockdown modulates cell cycle progression 
Cell cycle progression was determined following VIK siRNA knockdown in the VIK 
unmethylated, expressing breast cancer cell line, T47D. Flow cytometry was utilised to 
analyse cell cycle progression using DAPI staining for DNA content. Following 48 hours 
siRNA knockdown, there was very little difference in cell cycle progression in VIK siRNA 
knockdown cells compared to the non-targeting scrambled control (Figure 6.1A). At 72 
hours post transfection, significantly more cells were observed in G1 phase with an 
increase of 13% of cells in G1 phase in VIK knockdown cells (Figure 6.1B). This halt in G1 
was sustained at 96 hours post siRNA transfection, where again 13% more cells were seen 
in G1 phase in the VIK knockdown cells (Figure 6.1C). The increased number of cells in G1 
was accompanied by reduced proportion of cells in G2. These results indicate that, 
although the whole population of cells were not halted in G1 and some cells were still able 
to cycle normally, knockdown of VIK alters progression from G1 to S phase.  
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Figure 6.1 VIK siRNA knockdown alters cell cycle progression. VIK expressing T47D cells were 
transfected with a non-targeting scrambled siRNA or VIK targeting siRNA, cell cycle profile was 
assessed by flow cytometry analysis. A) VIK knockdown had no effect on cell cycle progression 
after 48 hours. B) 72 hours and C) 96 hours post transfection, significantly more cells were 
observed in G1 phase in VIK knockdown cells compared to scrambled siRNA. A representative 
cell cycle profile is shown of triplicate experiments. 2-way ANOVA *P<0.05 ***P<0.001. 
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6.1.2 VIK knockdown alters expression of G1/S phase checkpoint regulators 
To further confirm the effect of VIK on cell cycle progression in breast cancer cells, the 
expression of essential proteins involved in progression from G1 to S phase was 
investigated following VIK knockdown (Figure 6.2). VIK was knocked down via siRNA in the 
unmethylated breast cancer cell line T47D and the normal breast epithelial cell line 
MCF10A. siRNA knockdown of VIK led to changes in the level of multiple proteins that 
regulate the cell cycle in both T47D and MCF10A.  
In the T47D cancer cells CDK4 levels were not considerably altered, but there was a small 
downregulation in cyclin D. The downstream target of CDK4/cyclin D is the phosphorylation 
of Rb at serine 780. Knockdown of VIK led to a decrease in phosphorylated Rb at this site. 
Although there was also a decrease in total Rb, there was a larger reduction in Rb 
phosphorylation than in the total protein. Additionally the level of CDK1 was significantly 
decreased, along with CDK2, whilst the CDK2 binding partner, cyclin E, was significantly 
upregulated by 3-fold. E2F1, the key transcription factor in G1/S phase progression was 
also downregulated. There was a 3-fold increase of the cell cycle inhibitor p27. 
VIK knockdown also altered cell cycle protein expression in the normal MCF10A cells. CDK4 
was more significantly downregulated and there was a small decrease in cyclin D. Total Rb 
was decreased but there was a significantly larger reduction in phosphorylation of Rb. 
CDK1, CDK2 and E2F1 were all significantly decreased, whilst p27 increased. Unlike in the 
T47D cells, cyclin E remained unchanged in the MCF10A.  
These results suggest that VIK regulates expression of multiple cell cycle proteins. The 
changes in levels of the cell cycle proteins following VIK knockdown, are consistent with 
the observed cell cycle profile. Knockdown of VIK decreased expression of the key proteins 
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involved in progression from G1 to S phase, therefore corroborating the increased 
proportion of cells in observed in G1. As this was seen in both cancer and normal breast 
cell lines, this effect is not cancer specific. However, there might be different regulatory 
mechanisms in the normal compared to the tumour cell lines, as the upregulation of cyclin 
E was only observed in the tumour cells. This cyclin E upregulation might confer a survival 
advantage to tumour cells over normal cells, especially taking into account that the 
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Figure 6.2 VIK knockdown alters expression of proteins involved in cell cycle regulation. 
Following 72 hours of VIK siRNA knockdown in breast cancer cells T47D and normal breast 
epithelial cells MCF10A, protein expression of cell cycle regulators was determined by 
western blot. A) Example western blot of triplicate experiments. Protein expression was 
quantified relative to β-actin, and expression levels normalised to the non-targeting siRNA 
control in B) T47D breast cancer cells and C) MCF10A normal breast epithelial cells. 
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6.2 Loss of VIK is associated with resistance to CDK4/6 inhibitors 
6.2.1 VIK knockdown decreases sensitivity to the CDK4/6 inhibitor, palbociclib 
The CDK4/6 inhibitor palbociclib (Pfizer) is a novel therapy for the treatment of ER+HER2- 
breast cancer. As we have shown that knockdown of VIK expression in breast cancer cells 
modulated G1/S phase transition, and altered expression of cell cycle regulators, we 
investigated the effect of VIK on sensitivity to palbociclib in breast cancer cell lines. IC50 
values were determined in a panel of breast cancer cell lines with variable VIK expression 
and methylation (Figure 6.3A). Cell lines with an IC50 value above 1μM were defined as 
resistant as previously described by Finn et al (1). There was no association between 
methylation of VIK and sensitivity to palbociclib. There were varying IC50 values across the 
cell line panel, methylated and unmethylated cell lines exhibited both sensitivity and 
resistance to palbociclib. For example, the two resistant cell lines in the panel, MDA-MB 
468 and Jimt1, were VIK methylated and unmethylated respectively. This suggests that 
baseline VIK methylation status is not an indicator of palbociclib sensitivity.   
In the VIK expressing cell lines T47D and SUM44, the IC50 for palbociclib was determined 
upon VIK siRNA knockdown. Both T47D and SUM44 cells became more resistant to 
palbociclib after siRNA knockdown of VIK (Figure 6.3B). Upon knockdown of VIK there was 
a 7.6-fold increase in IC50 from 44nM to 334nM in T47D cells (Figure 6.3C). Whilst VIK 
knockdown in SUM44 cells lines caused and IC50 shift towards resistance from 200nM to 
1.3μM, an increase of 6.7-fold (Figure 6.3E). In the VIK methylated cell line MCF7, IC50 
values were determined after transient transfection with vector only (VO) or a VIK 
expressing vector. However, no difference was seen in IC50 values (Figure 6.3G). These 
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results suggest that VIK plays a role in palbociclib resistance in unmethylated, VIK 
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Figure 6.3. VIK and palbociclib sensitivity A) IC50 values across a panel of breast cancer cell 
lines. Cells were treated with increasing doses of palbociclib. After 6 days of drug 
treatment the concentration required to kill 50% of cells (IC50 value) was determined. B) 
IC50 shift following VIK siRNA knockdown in T47D cells. C) Average IC50 value in T47D cells 
following siRNA treatment D) IC50 shift towards resistance in SUM44 cells following VIK 
knockdown. E) Average IC50 values in SUM44 following siRNA treatment. F) IC50 curve for 
palbociclib following transfection with either vector only (VO) or VIK expressing vector on 
MCF7 cells and G) average IC50 values. A representative IC50 curve is shown of biological 
triplicates, % cell survival is normalised to DMSO vehicle control. *P<0.05 Students T-test.  
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6.2.2 VIK expression is lost in Palbociclib resistant cell lines  
Whilst clinical trials show many patients respond to treatment with palbociclib (235, 236), 
increasing clinical use is likely to lead to development of drug resistance. Understanding 
mechanisms of this resistance will be key to improving treatment. To investigate these 
mechanisms in vitro, palbociclib resistant cell lines were generated. The ER positive cell 
lines T47D and MCF7 were selected, as they were sensitive to palbociclib treatment and 
corresponded to VIK unmethylated and methylated respectively. Long-term culture with 
concentrations of palbociclib starting at 200nM and increasing to 1μM generated cell lines 
with acquired resistance to the drug. Three distinct resistant clones were selected for each 
cell line. MCF7 resistant clones M4, M5 and M8 and T47D resistant clones T5, T7, and T9. 
Resistant clones showed an IC50 shift from sensitive to resistant of approximately 220nM to 
at least 2μM for MCF7 and 200nM to 5μM for T47D, respectively (Figure 6.4). 




Figure 6.4. Generation of palbociclib resistant cell lines. MCF7 and T47D cells were 
cultured in increasing concentrations of palbociclib and resistant cells clonally selected. 
Three resistant clones for each cell line were chosen M8, M4 and M5 for MCF7 and T5, T7, 
T9 for T47D. A) A representative IC50 curve for sensitive and resistant clones after 6 days of 
drug treatment, all resistant clones for both MCF7 and T47D show a shift in IC50 towards 
resistance. B) Average IC50 value for each cell line. All clones have higher IC50 values than 
their corresponding sensitive parental cell line. Average +/- standard deviation is shown. 
*P<0.05 **P<0.01, 1-way ANOVA Tukey’s multiple comparison test. 
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Having established resistant cell lines, RNAseq was carried out to determine changes in 
gene expression following acquired resistance to palbociclib. The resistant cells derived 
from the methylated MCF7, showed little difference in VIK expression compared to 
sensitive. The T47D resistant clones, which are normally unmethylated and VIK expressing, 
showed down-regulation of VIK expression (Figure 6.5A). However, this was not statistically 
significant with adjusted p-values estimated by Benjamini-Hochberg procedure all >0.05. 
To validate the RNA sequencing results, RT-qPCR was performed (Figure 6.5B). In the MCF7 
resistant clones, there was no change in VIK expression and VIK mRNA remained 
undetectable. T47D cells with acquired palbociclib resistance showed significant reduction 
in VIK expression. In all three resistant clones VIK mRNA expression was reduced to barely 
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Figure 6.5. VIK mRNA expression in palbociclib resistant cell lines. A) Fold change of VIK 
expression as determined by RNA sequencing in MCF7 palbociclib resistant clones (M4, 
M5, M8) and T47D resistant clones (T5, T7, T9). Expression values are log fold change 
relative to the sensitive control cells, where <0 indicates a downregulation in expression. 
B) Validation of RNAseq by RT-qPCR VIK. mRNA was undetectable in both sensitive and 
resistant MCF7 lines. VIK was significantly decreased in all T47D resistant clones. ** 
P>0.01 1-way ANOVA Tukey’s post-hoc comparison test. 
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6.3 Summary 
VIK was identified as a novel regulator of the cell cycle in breast cancer. Knockdown of VIK 
altered the expression of multiple proteins regulating the cell cycle, in particular the G1/S 
phase transition, inducing cells to arrest in G1. This effect on cell cycle proteins was not 
tumour specific, but was also observed in normal breast epithelial cells. Although there 
were some differences in the tumour cells compared to the normal cells, indicating 
potential different regulatory mechanisms.  
Loss of VIK was associated with resistance to the CDK4/6 inhibitor, palbociclib. siRNA 
knockdown in VIK expressing cells led to an increase in IC50 values. Additionally VIK mRNA 
expression was lost in cell lines with acquired resistance to palbociclib. In combination 
these results show loss of VIK in endogenously expressing breast cancer cells does have a 
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7.1 Overview 
VIK was initially identified as of interest in breast cancer following a methylation array 
detecting aberrant methylation across the CpG island in breast cancer cell lines. 
Preliminary analysis of primary breast cancer patient samples associated VIK methylation 
with decreased survival in estrogen receptor positive breast cancer. Functionally, VIK is not 
well characterised, except it is a member of the Krüppel-like transcription factor family, 
and the protein interacts with VAV1 and CDK4 to block cell cycle progression (277).  
In this thesis I have demonstrated VIK to be epigenetically regulated on a transcriptional 
level, although this may not translate to protein expression. Analysis of patient samples 
revealed methylation in approximately 8-14% of breast cancer samples, however this could 
not be correlated to patient outcome. In vitro analysis established expression of VIK to be 
important to cell survival in both normal and cancer cell lines. Decreased VIK expression 
induced apoptosis via cell cycle arrest in G1. This suggests a role for VIK in regulating cell 
cycle progression through the G1/S phase checkpoint. This role could be of particular 
importance in the context of CDK4/6 inhibition, where I have demonstrated loss of VIK 
expression to might be involved in development of acquired resistance to CDK4/6 
inhibitors.  
7.2 Methylation transcriptionally silences VIK 
The methylation array identified the CpG island within the 5’ regulatory region of the gene 
to be highly methylated within breast cancer cell lines. Methylation dependent 
transcriptional silencing was further confirmed upon methylation analysis via 
pyrosequencing. Transcription of VIK is clearly epigenetically regulated, there is a direct 
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correlation between methylation and mRNA expression. In cell lines with methylation 
above 30%, no detectable mRNA was observed across any of the RT-qPCR assays utilised. 
Additionally, demethylation treatment released the transcriptional repression in 
methylated cell lines and upregulated mRNA levels. This epigenetic regulation is supported 
by the TCGA data in primary patient samples, with higher VIK methylation correlating to 
decreased mRNA expression in the tumour samples.  
However, in our cell line panel, protein levels, as determined by western blot, did not 
correlate with mRNA levels. Using three antibodies (2 commercially available and a single 
custom), all showed similar trend.  In unmethylated cell lines, mRNA and protein were both 
expressed as expected. However, in the methylated cell lines, protein was expressed 
despite the lack of mRNA expression. We were unable to correlate or confirm our results as 
there is only one published paper regarding VIK protein expression, where a custom 
antibody was used, and there is no published data on VIK protein expression in breast 
cancer cells.  
siRNA treatment knocked down both mRNA and protein in the unmethylated cell line, this 
could suggest the antibodies are detecting the correct protein in unmethylated cell lines. 
However, it should be considered that the most likely explanation is that the antibodies 
tested are incorrect or are not fit for the purpose of detecting VIK expression by western 
blot and the protein bands we observe are unspecific. Each antibody detected a different 
size, with the custom antibody detecting 80kDa, not corresponding to any known transcript 
of VIK. Additionally, each antibody did show different protein levels across the same cell 
line panel. Ectopically expressed VIK by means of the pcDNA3.1-VIK vector did not alter 
detectable protein levels, despite increase in mRNA. Although the inability to detect 
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transfected over-expressed VIK could instead be due to some misfolding or rapid 
degradation of the protein, not allowing for antibody detection. However, even upon 
methylation reversal, upregulation of mRNA did not correspond to increased protein levels. 
In fact, the only instance where detection of increased mRNA levels was accompanied with 
an increase in protein was with the unmethylated cell line in hypoxic conditions. However, 
in the context of a stress response in hypoxia, proteins are often stabilised rather than an 
increase in protein synthesis, so the increase in protein levels could be due to stabilisation 
of the protein, rather than an induced expression. Additionally, upon, immunofluorescence 
analysis the antibody detected a primarily cytoplasmic protein, when the only published 
data on VIK-1 protein expression showed VIK to be predominantly nuclear (277). 
Localisation of the protein does not disprove the protein expression, as VIK has been 
shown to shuttle between the nucleus and the cytoplasm due to a nuclear import and 
export sequence (277). However, rather than just looking at baseline protein, 
immunofluorescence following siRNA treatment to determine depletion of the protein 
would provide more information of the specificity of the antibody. 
As the antibody data was unclear, we sought to confirm if the antibodies were correctly 
detecting VIK by means of an IP assay. Unfortunately we were unable to perform an 
endogenous IP with our antibodies. This would have been ideal, as the endogenous protein 
in methylated and unmethylated cell lines could be compared. Instead, an IP was 
performed on overexpressed pEGFP-VIK. When the IP sample was probed back for GFP and 
VIK, the same band was seen. Mass spectrometry for this band revealed presence of VIK, 
providing evidence for the antibodies detecting the protein correctly. However, over a 
hundred other proteins were also detected, most likely these are unspecific proteins. The 
high number of other proteins could potentially indicate VIK has a number of protein 
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binding partners. This would be expected based on the structure of VIK, which has 6 
tandem zinc fingers. Zinc finger domains are known to have activity for protein-protein 
interactions (294). A number of the proteins identified after mass spectrometry were heat 
shock proteins, which could act as chaperone proteins for VIK. For example Heat Shock 
protein 90 was a top hit and is known to act as a molecular chaperone for stability of 
proteins involved in cell growth and proliferation in cancer.  
However, if there is the protein is present in methylated cell lines, this raises the question; 
if methylation means repressed transcription and no detectable levels of mRNA, how can 
protein be present in methylated cell lines?  In this case an alternative hypothesis is that all 
cell lines have a basal expression of protein, potentially inactive, with a long half-life, that is 
easily detectable by western blot, whilst mRNA is readily degraded and below the 
detectable qPCR levels. Other proteins involved in cell cycle regulation exhibit a similar 
expression pattern to this, with a constant baseline protein expression followed by 
transient peaks in synthesis. For example, cyclin D shows cell cycle-dependent oscillation in 
expression and is upregulated in G1 for orderly progression into S phase (295).  
It is often reported that protein levels do not correlate strongly to mRNA levels, with 
changes on the gene expression level frequently not reflected at the protein level (296). 
Short mRNA stability and long half-life of proteins is cited as a big factor, in addition to a 
low rate of mRNA transcription compared to protein translation in mammalian cells (297). 
Cooper and Shedden suggest this can be particularly complicated with regards to the cell 
cycle, concluding that changes in mRNA levels have only a minimal effect on protein 
variation during the cell cycle (298). The 3’UTR plays an important role in determining the 
translational efficiency and stability of mRNA, primarily due to the addition of a poly A tail 
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and microRNA (miRNA) binding sites (299). Transcripts encoding proliferative genes and 
proto-oncogenes tend to have longer 3’UTRs, and a longer 3’UTR can indicate increased 
number of miRNA binding sites (300), which could lead to increased mRNA degradation. All 
VIK transcripts do have a particularly long 3’UTR of approximately 2869 bases, which could 
be indicative of targeted degradation of the mRNA. It is increasingly understood that 
epigenetic changes do not act in isolation, but DNA methylation regulates miRNA 
expression (301) and methylation can be regulated by miRNAs (302, 303). Therefore genes 
may be subject to multiple regulatory controls such as both DNA methylation and miRNA 
degradation. Although correlation between gene methylation and miRNA targeting has not 
been largely explored, it has been suggested that genes with promoters containing high 
CpG content are more often targeted by miRNAs (304). There are examples of genes such 
as suppressor of cytokine signalling (SOCS3), which functions as a tumour suppressor in 
breast cancer and is subject to both methylation and miRNA mediated epigenetic 
regulation (305, 306). 
In the case of a rapidly degraded mRNA and basal protein expression in all cells, the 
baseline protein would likely have a long half-life or slow turnover and there could 
potentially be a difference in protein stability between methylated and unmethylated cells. 
Furthermore, it could be the case that control of production of VIK protein is tightly 
regulated, it would then be likely that the baseline protein and induced protein have a 
difference in stability i.e. the baseline levels of VIK are stable, however the upregulated 
levels of VIK are unstable. If protein expression is induced unnecessarily, the protein is 
quickly degraded when cells produce more than is required. It would be of interest to 
determine half-life of the protein by treatment with cycloheximide to inhibit biosynthesis 
and measuring the length of time required for the protein to be depleted. VIK could have 
Chapter 7: Discussion 
174 
multiple binding partners, which could increase stability of the protein. Additionally, the 
baseline protein could be inactive and require a post translational modification for 
activation, such as phosphorylation, glycosylation or ubiquitination. Potential evidence for 
this is seen by the different sizes detected by different antibodies.   
If it is the case that all cell lines exhibit a stable baseline protein then methylation of the 
promoter region might inhibit inducible upregulation of the gene, by actively inhibiting 
binding of required transcription factors within the gene promoter region. We see some 
evidence of this on the mRNA level, via knockdown of VAV1 leading to an increase in VIK 
mRNA expression in the VIK unmethylated cell line, whilst there is no induction of VIK 
mRNA in the methylated cell line. Additionally in hypoxia, we observed induced 
upregulation of mRNA levels in the unmethylated cell line but not the methylated cell line.  
There is no published data regarding regulation of VIK transcription by transcription 
factors. Although as mentioned in results chapter 2, analysis of the DNA sequence of the 
CpG island within the regulatory domain of the VIK gene showed putative binding sites for 
over 150 transcription factors including the FOX family and STAT family. We experimentally 
tested induction by TGF-β and EGF, however no real effect was seen on induction of VIK 
expression with the conditions tested. Based on the large number of putative transcription 
binding sites, to further analyse the control of VIK by transcriptional regulators 
experimentally, a more systematic approach would be required. For example, mutations of 
the promoter region could be produced and transcription of the gene measured by use of a 
luciferase reporter assay. This could determine precisely which region of the promoter 
region transcription is dependent upon and what transcription factor might bind to that 
particular region.   
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7.3 Methylation of the VIK promoter region is prevalent in breast 
tumour tissue 
Having established methylation within breast cancer cell lines, and based on a preliminary 
patient cohort where methylation was associated with shorter overall patient survival, we 
wanted to confirm if VIK could be a prognostic biomarker in breast cancer. We confirmed 
within primary breast cancer patient samples that there are a proportion of patients where 
VIK expression is subject to methylation dependent transcriptional silencing. VIK 
methylation was observed to be higher in tumour samples, with non-tumour samples 
showing no methylation for VIK. Moreover, higher methylation significantly correlated to 
decreased mRNA expression. Two patient cohorts were analysed; one experimental (Leeds 
cohort) and one in silico (TCGA cohort). Methylation of the two cohorts was determined via 
two different methods. The Leeds cohort was analysed using pyrosequencing, covering 6 
individual CpG sites over a small portion of the CpG island, 259 nucleotides out of a large 
CpG island of 1059 nucleotides in total. For the TCGA cohort methylation array data was 
available, covering 13 CpG sites across the whole CpG island region. As shown in chapter 1, 
the methylation array and pryosequencing had a strong correlation between methylation 
values in our cell line samples. When analysing the region of the CpG island covered by the 
pyrosequencing primers, methylation of VIK was of similar prevalence in both cohorts, 7% 
and 9% in the Leeds and TCGA cohorts respectively. This was slightly lower than the 
preliminary cohort, where 15% of patients were methylated. Methylation in the 
preliminary cohort was determined by means of methylation specific PCR (MSP), compared 
to pyrosequencing for the Leeds cohort and methylation array for TCGA dataset. The MSP 
primers used to assess methylation within the preliminary cohort covered CpG sites 
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upstream of the pyrosequencing assay. The region of the CpG island analysed might be of 
more importance, especially considering the methylation array from TCGA dataset showed 
more variation across the CpG island within the patient tumour samples than was observed 
in our own methylation array in the breast cancer cell lines. When methylation across the 
whole CpG island was taken into account the number of methylated samples was increased 
to 14%, a similar proportion to the preliminary cohort. Considering this, the different 
determination of methylation and region of the CpG island analysed for the preliminary 
cohort could account for the discrepancy between the proportion of methylated 
populations within the Leeds cohort. 
The preliminary patient cohort showed a trend for poorer survival in patients with 
methylated VIK. However, within the two patient cohorts examined we were unable to 
confirm this observed trend. There was no significant difference in overall survival times in 
the methylated or unmethylated populations in either cohort. This difference could be due 
to the fact the preliminary cohort consisted of only estrogen receptor positive breast 
cancer patients, whereas both the cohorts examined within this thesis were of mixed 
hormone status. Due to the small proportion of methylated samples, we were unable to 
examine the estrogen receptor positive population only within our cohorts to directly 
compare to the preliminary cohort.  Furthermore, within the TCGA dataset, there were too 
few survival events across the cohort to properly assess the impact of VIK methylation on 
patient outcome. Whilst the Leeds cohort was not large enough considering the small 
number of patients within the methylated group. Due to these reasons, the survival data 
from these cohorts is inconclusive. Further analysis with larger patient sample size would 
be required to further elucidate the effect of methylation on patient outcome and use of 
VIK methylation as an indicator of patient prognosis. Although we were unable to confirm 
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methylation of VIK as a prognostic marker, our patient cohorts suggest there is a small 
population of breast cancer patients in which VIK is transcriptionally repressed by 
methylation. 
7.4 VIK is not a determinant of sensitivity to endocrine therapy 
The preliminary patient cohort associated methylation of VIK with lower ER expression, 
and increased risk of recurrence in tamoxifen treated patients. This, in addition to the 
decreased overall survival in tamoxifen treated patients, indicated a role for VIK in 
resistance to endocrine therapy. Although, we were unable to replicate the differential 
outcome with regards to VIK methylation in our patient cohorts, we did investigate the 
potential role for VIK in endocrine resistance in vitro. There is precedence for KLFs 
interacting with estrogen signalling. Other KLFs have been shown to bind to the DNA 
binding region of ERα, thereby modulating the binding of ERα to endocrine response 
elements (ERE) within target genes (307, 308) and there is evidence for KLF induction via 
estrogen signalling (309, 310). However, estrogen stimulation in breast cancer cell lines did 
not induce VIK expression. This is supported by published ER binding studies. Multiple 
approaches have been applied to determine ER target genes including genome wide arrays 
and high throughput chromatin immunoprecipitation sequencing data (ChIP-Seq), from 
which supplementary material including gene expression arrays and ER binding site data is 
accessible. Within the available data, there is no evidence for VIK being differentially 
expressed upon estrogen induction or for ER directly interacting within gene regulatory 
sequences for VIK in breast cancer cells (310-312). In addition to this, VIK did not correlate 
to ER expression within the cell line panel; VIK was not differentially methylated in ER+ 
breast cancer in comparison to other subtypes. Furthermore, knockdown of VIK did not 
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alter sensitivity to tamoxifen, this indicates no direct link between VIK and endocrine 
resistance with regards to tamoxifen treatment.  As we were unable to confirm our initial 
hypothesis of an involvement of VIK in endocrine resistance, we instead focused on 
identifying other functional roles for VIK in breast cancer.  
7.5 VIK expression is important for cell survival 
We sought to further determine the functional role for VIK in breast cancer using siRNA 
knockdown of VIK in cell lines that were unmethylated and VIK expressing. Our first 
observation was that reduction in VIK levels caused cell death. Ideally more than one siRNA 
would have been used to confirm the effects seen were not due to off target effects, 
however VIK was not easy to knockdown, and when knockdown was successful there were 
significant levels of cell death. Unfortunately the levels of cell death with the second siRNA 
made it unsuitable for use in other assays as there were too few surviving cells remaining 
at the end point. The ideal situation would have been use of an inducible knockdown 
system, such as use of a Tet Repressor and lentiviral shRNA transduction, which would 
provide a more stable knockdown system.  
It is clear from our data that modulation of VIK levels cannot be tolerated by cells, both 
over expression and knockdown caused cell death. This implies that cells have an optimal 
VIK expression level, and cells cannot survive disruption of this. Although it should be 
noted that transfection with the VIK expression plasmid led to over-expression of VIK 
beyond physiological mRNA levels in endogenously expressing VIK cell lines. Therefore the 
cell death could be due to extra stress on the cells due to such high levels of VIK mRNA.  
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Loss of VIK expression via siRNA induced significant levels of cell death. While this was true 
for both normal and tumour breast cell lines, the non-tumour cells appeared more 
sensitive to cell death following VIK knockdown. Further analysis revealed loss of VIK 
induced cells to enter apoptosis; this would suggest that VIK expression normally protects 
cells from apoptotic cell death. Consequently, VIK expression is important to cell survival.  
7.6 VAV1 and VIK reciprocal expression upon knockdown 
Aside from cell death, our second observation following VIK knockdown was an 
upregulation of VAV1. The function of VIK to date is not well characterised, however it is 
known that VIK has a direct interaction with VAV1. Previous evidence shows over-
expression of VIK halts the cell cycle in G1, whilst co-expression with VAV1 reverses this 
inhibitory effect to drive cell cycle progression forward (313). 
Although there was no direct correlation between VIK and VAV1 expression across a panel 
of breast cancer cell lines, knockdown of VIK in unmethylated cell lines did lead to a 
compensatory increase in VAV1, and knockdown of VAV1 led to an upregulation of VIK. 
This supports the hypothesis of a dual role for these two proteins, and a potential feedback 
between the two. However, the upregulation of VAV1 occurred at day 3 following VIK 
knockdown and cells still continued to die past day 5, which suggests the upregulation of 
VAV1 does not provide a survival advantage for the cells.  
Additionally, the reciprocal expression of VIK and VAV1 was not further supported in 
patient tissue samples. VIK was downregulated in breast cancer samples in comparison to 
normal breast tissue and conversely VAV1 was upregulated. However, this was not true in 
those patients who were specifically VIK under-expressing. In the patient cohorts analysed 
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there was no direct correlation between VIK expression and VAV1 expression, and there 
was no difference between VAV1 expression in VIK -high or -low expressing samples. There 
is no published data on VIK expression in tumour samples, but the VAV1 expression is in 
concordance with other work. It is known that VAV1 expression is normally 
haematopoietic-restricted, and aberrant expression has been demonstrated in a number of 
human cancers, including breast (277), brain (274) and pancreatic (266). Our cell line data 
in combination with the patient samples could indicate that VIK and VAV1 only transiently 
compensate for each other. When one is lost the other is upregulated initially to 
compensate. However, there is no long-term compensation for each other and the 
dynamics of VIK and VAV1 expression may not be so important in primary breast cancer, 
potentially the observed initial compensatory upregulation is functionally redundant.  
7.7 VIK is involved in cell cycle progression 
In addition to its interaction with VAV1, VIK-1 has been shown to interact with CDK4 and 
overexpression was shown to halt the cell cycle in G1 (270). Therefore, the initial 
hypothesis was that the interaction of VIK and CDK4 would inhibit CDK4 activity. 
Consequently, knockdown of VIK should result in release of this inhibition leading to 
increased Rb phosphorylation, and progression from G1 to S phase. However, this effect 
was not observed, in fact the reverse was true and VIK knock down induced arrest in G1, 
indicating the interaction between CDK4 and VIK is not inhibitory. The published study 
used a leukaemia cell line, and there is no published data on the role of VIK in breast cell 
lines, so potentially the role of VIK in cell cycle regulation is tissue dependent. This would 
not be unexpected, as other Krüppel-like factors have diverse context dependent 
functions. KLF5 is associated with shorter disease free survival in breast cancer (277) but 
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improved outcome in lung cancer (314). KLF4, in particular, depending on the cellular 
context, can function as a tumour suppressor e.g. in colon (315), gastric (254) and 
pancreatic cancers (316), or an oncogene, e.g. in squamous epithelial dysplasia (317) or 
breast cancer (318-320). 
In breast cells, VIK knockdown resulted in altered expression of a number of proteins 
involved in the G1/S phase transition and halted cells in G1 (Figure 6.2). This demonstrates 
VIK expression is required for normal cell cycle progression. The changes in cell cycle 
proteins were observed in the normal breast cell line as well as the breast cancer cell line, 
showing a more universal role for VIK within the cell cycle rather than a cancer specific 
role. Some changes in proteins were similar in both the tumour and normal cell line i.e. 
downregulation of pRb, CDK1, CDK2, E2F1 and upregulation of p27. Yet there were some 
differences, increase in cyclin E in occurred in tumour cells only and CDK4 was only 
significantly decreased in normal cells. This indicates there are different mechanisms 
occurring in the normal and tumour cells. 
Phosphorylation of Rb at serine 780 was markedly reduced in both the normal and tumour 
cell line. This site is phosphorylated by CDK4/cyclin D complexes. Cyclin D was only 
downregulated to a small degree in both cell lines. In the normal cell line there was a 
marked reduction in CDK4, which could explain the reduced pRb. In the tumour line there 
was only minimal change in CDK4, and the small reduction in cyclin D is unlikely to be 
sufficient to result in the significant reduction in Rb phosphorylation. The decrease in pRb 
is more likely to be due to the upregulation of the cell cycle inhibitor p27(Kip), which was 
notably increased in both the normal and cancer lines. Overexpression of p27 binds to and 
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prevents the activity of CDK4, inhibiting the phosphorylation of Rb and arresting cells in G1 
(321). 
It should be noted that within the tumour cells there was a modest halt of cells in G1 
rather than a complete halting of cells, and some VIK knockdown cells were still able to 
progress through to S phase. Aside from CDK4 being downregulated to a much greater 
extent in the normal breast cells, the other primary difference between normal and 
tumour cells was upregulation of cyclin E in the tumour cell line only. The upregulation of 
cyclin E in the tumour cells could suggest the cells are trying to compensate for the other 
cell cycle changes to continue normal cell cycle progression. The loss of phosphorylated Rb 
and marked reduction in E2F1, indicates this increase in cyclin E must be independent of 
the normal Rb/E2F control. It has been shown that over-expression of cyclin E is sufficient 
to override G1 arrest imposed by CDK4/6 inhibition or lack of pRb (322). Cyclin E 
transcription can be induced by other signalling pathways such as c-myc, independently of 
E2F (323). The normal breast cell line had a greater reduction in CDK2 and was unable to 
upregulate cyclin E. The normal cells were also more sensitive to cell death following VIK 
knockdown. Potentially, the ability to upregulate cyclin E could assist cell survival following 
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Figure 7.1 Hypothesised schematic of cell cycle regulation in normal breast cells and 
breast tumour cells upon loss of VIK expression. A) VIK expressing cells with normal cell 
cycle progression. CDK4/cyclin D complexes phosphorylate Rb. Phosphorylated Rb 
dissociates from E2F, enabling transcription of cyclin E. CDK2/cyclin E complexes further 
phosphorylate Rb, leading to complete dissociation from E2F enabling transcription of 
required S phase genes. B) In non-tumour breast cells loss of VIK causes upregulation of 
p27, which inhibits CDK4/6 mediated phosphorylation of Rb, therefore inducing cell cycle 
arrest at G1. C) In breast cancer cells loss of VIK causes upregulation of p27, which inhibits 
CDK4/6 mediated phosphorylation of Rb, inducing some cell cycle arrest in G1. However, 
loss of VIK also induces Rb/E2F independent upregulation of cyclin E, allowing some cells to 
drive cell cycle progression forward.  
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The marked changes in multiple cell cycle proteins, CDK1, CDK2, p27, cyclin E, E2F1, 
indicates that VIK has an effect outside of just direct interaction with CDK4. In other 
cancers, members of the Krüppel-like factor family are known to be involved in cell cycle 
regulation via their functions as DNA-binding transcriptional regulators. For example in 
pancreatic cancer, KLF4 results in G1 arrest through induction of the CDK inhibitors p21 
and p27, KLF5 has been shown to induce cyclin D in bladder cancer (324), whilst KLF6 
activates p21 in prostate cancer (295). Potentially VIK also exerts regulation on the cell 
cycle via transcriptional activation or repression of cell cycle genes e.g. repression of E2F1, 
or activation of p27 or cyclin E transcription. To properly examine the transcriptional 
regulatory role of VIK, chromatin immunoprecipitation would be required to determine 
regions of DNA the protein binds to. Unfortunately, in part due to the complications with 
anti-VIK antibodies, this was beyond the scope of this PhD. 
The cell cycle data in combination with the induction of apoptosis and cell death, indicates 
that loss of VIK induces cells cycle arrest at G1, inducing cells to enter apoptosis. It is likely 
that the role of VIK is more complicated than just the published interaction with CDK4 and 
VAV1. VIK has zinc finger domains, which could suggest transcriptional regulatory activity 
but would also aide multiple protein-protein interactions. It is also of interest to note that 
following IP for VIK multiple proteins were detected. Many of these proteins were all 
involved within DNA damage response (PARP (243), XRCC5 (325), SSRP1 (326), DDX21 
(327), NUCL (328)), suggesting VIK might interact with these proteins and could therefore 
also be involved in this pathway. It is possible VIK acts as a chaperone or adaptor protein 
involved in mediating response to DNA damage. Although, further work would be required 
to investigate this. In response to DNA damage cells can be arrested in G1 to provide time 
Chapter 7: Discussion 
185 
for cells to repair the damage and proceed into S phase or enter apoptosis if the damage is 
not repaired (329).  
7.8 Potential role for VIK in acquired resistance to CDK4/6 inhibition 
CDK4/6 inhibitors are currently one of the most promising novel therapies in ER positive 
breast cancer, and with increasing clinical use understanding of resistance mechanisms is 
essential. VIK appears to have a role in resistance to CDK4/6 inhibition in ER positive cell 
lines. Sensitivity to the selective CDK4/6 inhibitor palbociclib was not linked to baseline VIK 
expression or methylation. However, in cell lines that are VIK expressing, these results 
suggest VIK potentially does play a role in resistance to the drug. Whilst over-expression of 
VIK did not alter sensitivity in the methylated MCF7 cells, siRNA knockdown of VIK in 
unmethylated cell lines showed a significant shift towards palbociclib resistance. 
Additionally T47D clones with acquired palbociclib resistance, whose parental cell line is 
VIK expressing, showed significant downregulation of VIK to barely detectable levels. This 
demonstrates that in cells that are endogenously expressing VIK, loss of expression might 
confer resistance to palbociclib. To further confirm the role of VIK in resistance, re-
expression of VIK into cells with reduced VIK expression could be utilised to determine if 
re-expression of VIK resensitises resistant cells to palbociclib. Whilst baseline VIK 
expression is not an indicative biomarker for resistance to palbociclib, loss of VIK 
expression over the course of treatment could be a predictive marker for acquired 
palbociclib resistance.  
The decreased VIK mRNA levels in palbociclib resistant cells could either be due to reduced 
levels of transcription or increased degradation of the mRNA. It would have been 
interesting to see that the loss of VIK mRNA expression in palbociclib resistant cells is 
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accompanied by a change in methylation status. However, preliminary results indicate this 
is not the case, with initial pyrosequencing analysis showing both the sensitive parental 
T47D cell line and the palbociclib resistant clones are unmethylated (Figure 7.2). Instead, 
VIK expression in the resistant clones could be altered by other epigenetic changes, such as 
histone modification. For example, decreased levels of histone acetylation could lead to a 
more closed chromatin structure. This would limit accessibility of transcription complexes 
to the DNA, therefore inhibiting transcription of the gene (330). Alternatively, the loss of 
VIK expression could be due to increased microRNA mediated degradation of the mRNA. 
microRNAs are increasingly documented to have a role in drug resistance in breast cancer 
(331). In fact, computational prediction of miRNA binding sites using TargetScan (332) 
shows the 3’UTR for VIK has multiple conserved miRNA binding sites. For example, miR-
181a which has previously been implicated in promoting metastasis (333) and 
chemotherapeutic resistance (334) in breast cancer. Increased activity of this miRNA in 












Figure 7.2 Preliminary pyrosequencing analysis of palbociclib resistant T47D clones. 
Sensitive parental T47D cells and palbociclib resistant clones were analysed for 
methylation by pyrosequencing. The percentage methylation of 7 individual CpG was 
assessed and average over 7 all sites calculated to determine percentage methylation for 







Chapter 7: Discussion 
188 
Initially it was hypothesised that VIK could be involved in resistance via the previously 
published direct interaction between VIK and CDK4 (335). Palbociclib inhibits CDK4/6 by 
competitively targeting the ATP binding pocket. VIK as a binding partner of CDK4, could 
potentially alter the drug binding to and inhibiting of CDK4 itself. However, our results 
argue against this theory. Upon VIK knockdown we observed decreased phosphorylation of 
Rb. Therefore, cells with knockdown of VIK acquire resistance to palbociclib because the 
target of the drug is already downregulated as a result of the VIK knockdown. However, the 
involvement of VIK in palbociclib resistance is unlikely to be simply down to this as we see 
VIK itself is lost in resistant cells. As discussed above, knockdown of VIK altered multiple 
cell cycle proteins. Therefore, it is more likely that loss of VIK is involved in upregulation of 
other cell cycle proteins or other signalling pathways that allow the cells to further escape 
the CDK4/6 inhibition. As previously discussed, knockdown of VIK upregulated cyclin E. This 
same upregulation of cyclin E is observed in cell lines with acquired resistance to 
palbociclib promoting cell cycle entry (336). Therefore, we hypothesise loss of VIK induces 
upregulation of cyclin E, which is could to contribute to survival of palbociclib resistant 
cells.
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8 Conclusions 
This thesis confirms VIK as a novel gene in breast cancer subject to methylation dependent 
transcriptional silencing. I have shown for the first time that VIK is differentially methylated 
in breast tumour samples compared to normal breast tissue. Expression of VIK is essential 
for both normal breast and breast cancer cell survival. Upon downregulation of VIK, VAV1 
was upregulated, although this did not appear to rescue cells from cell death. Loss of VIK 
induces apoptosis through modulation of cell cycle proteins and cell cycle arrest in the G1 
phase. Thus demonstrating VIK expression is required for normal cell cycle progression in 
breast cells. This role of VIK in cell cycle regulation is of particular interest as CDK4/6 
inhibitors, such as palbociclib, have been increasingly recognised as effective in 
combination with endocrine therapy in breast cancer treatment. With increasing clinical 
use, resistance to palbociclib will become an important clinical issue, an understanding of 
resistant mechanisms will be crucial. I have demonstrated that loss of VIK is potentially 
involved in development of acquired resistance to CDK4/6 inhibitors. This would make VIK 
one of the first novel genes to be linked to resistance to this new class of drug for 
treatment of breast cancer.  
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